https://curecurrent.com/trials/safety-of-liraglutide-in-pediatric-patients-with-type-2-diabetes-6001https://curecurrent.com/trials/effects-of-prevena-therapy-on-obese-and-or-diabetic-patients-with-surgical-groin-sites-6002https://curecurrent.com/trials/effect-of-liraglutide-on-blood-glucose-control-in-subjects-with-type-2-diabetes-6003https://curecurrent.com/trials/effect-of-liraglutide-on-heart-frequency-in-healthy-volunteers-6004https://curecurrent.com/trials/glucose-variability-pilot-study-for-the-abbott-sensor-based-glucose-monitoring-system-professional-6005https://curecurrent.com/trials/accuracy-characterization-study-6006https://curecurrent.com/trials/personalized-health-planning-in-shared-medical-appointments-for-individuals-with-type-ii-diabetes-pilot-study-6007https://curecurrent.com/trials/the-effect-of-nn1250-in-subjects-with-type-2-diabetes-of-different-race-and-or-ethnic-origin-6008https://curecurrent.com/trials/weight-changes-during-and-after-pregnancy-in-women-with-gestational-diabetes-6009https://curecurrent.com/trials/a-trial-comparing-sequential-addition-of-insulin-aspart-versus-further-dose-increase-with-insulin-degludec-liraglutide-i-6010https://curecurrent.com/trials/diabetes-attitudes-wishes-and-needs-6011https://curecurrent.com/trials/comparison-of-glycemic-control-achieved-with-2-different-needles-6012https://curecurrent.com/trials/a-study-to-investigate-the-safety-and-metabolism-of-gsk376501-in-overweight-subjects-6013https://curecurrent.com/trials/neck-grasp-as-a-predictor-of-sleep-apnea-6014https://curecurrent.com/trials/a-trial-investigating-nn1218-in-subjects-with-type-1-and-type-2-diabetes-6015https://curecurrent.com/trials/ziprasidone-for-clozapine-or-olanzapine-associated-diabetes-mellitus-6016https://curecurrent.com/trials/alliance-to-control-diabetes-6017https://curecurrent.com/trials/gapp-2-survey-global-attitudes-of-patients-and-physicians-in-insulin-therapy-for-type-2-diabetes-mellitus-6018https://curecurrent.com/trials/vaccine-efficacy-in-diabetic-and-elderly-patients-6019https://curecurrent.com/trials/switching-from-one-type-of-anti-rejection-drug-tacrolimus-or-cyclosporine-to-another-sirolimus-approximately-90-180-days-6020https://curecurrent.com/trials/comparison-of-biphasic-insulin-aspart-70-30-versus-insulin-glargine-in-subjects-with-type-2-diabetes-6021https://curecurrent.com/trials/albiglutide-glucose-clamp-study-in-subjects-with-type-2-diabetes-6022https://curecurrent.com/trials/comparison-of-biphasic-insulin-aspart-70-30-with-anti-diabetic-drugs-in-subjects-with-type-2-diabetes-6023https://curecurrent.com/trials/a-study-to-determine-the-safety-and-efficacy-of-albiglutide-administered-in-combination-with-insulin-glargine-6024https://curecurrent.com/trials/hepatic-dysfunction-vitamin-d-status-and-glycemic-control-in-diabetes-6025https://curecurrent.com/trials/development-of-nic5-15-in-the-treatment-of-alzheimer-s-disease-6026https://curecurrent.com/trials/biphasic-insulin-aspart-30-in-type-2-diabetes-failing-oad-therapy-6027https://curecurrent.com/trials/the-synergy-to-control-emergency-department-hyperglycemia-program-for-type-2-diabetes-6028https://curecurrent.com/trials/efficacy-and-safety-of-albiglutide-in-treatment-of-type-2-diabetes-6029https://curecurrent.com/trials/a-study-to-determine-the-safety-and-efficacy-of-albiglutide-in-patients-with-type-2-diabetes-6030https://curecurrent.com/trials/safety-and-efficacy-study-of-albiglutide-in-type-2-diabetes-6031https://curecurrent.com/trials/pharmacokinetics-pharmacodynamics-of-albiglutide-6032https://curecurrent.com/trials/a-study-to-determine-the-safety-and-efficacy-of-albiglutide-in-subjects-with-type-2-diabetes-6033https://curecurrent.com/trials/safety-and-efficacy-of-albiglutide-in-type-2-diabetes-6034https://curecurrent.com/trials/a-randomised-trial-evaluating-continuous-subcutaneous-infusion-of-formulations-of-nn1218-and-novolog-in-subjects-with-ty-6035https://curecurrent.com/trials/reliability-of-dosing-with-novolog-mix-70-30-flexpen-compared-with-vial-and-syringe-6036https://curecurrent.com/trials/januvia-sitagliptin-in-healing-chronic-diabetic-foot-ulcers-6037https://curecurrent.com/trials/comparison-of-two-biphasic-insulin-aspart-30-formulations-current-and-new-formulation-in-healthy-volunteers-6038https://curecurrent.com/trials/effects-of-biphasic-insulin-aspart-70-30-vs-exenatide-in-type-2-diabetes-patients-not-reaching-blood-glucose-targets-on-6039https://curecurrent.com/trials/novolog-observation-trial-in-subjects-with-type-1-and-type-2-diabetes-6040https://curecurrent.com/trials/efficacy-and-safety-of-lixisenatide-versus-insulin-glulisine-on-top-of-insulin-glargine-with-or-without-metformin-in-typ-6041https://curecurrent.com/trials/prevention-trial-to-achieve-cardiovascular-targets-6042https://curecurrent.com/trials/effect-of-metabolic-control-at-onset-of-diabetes-on-progression-of-type-1-diabetes-6043https://curecurrent.com/trials/a-study-of-bms-512148-dapagliflozin-in-patients-with-type-2-diabetes-with-inadequately-controlled-hypertension-on-an-ace-6044https://curecurrent.com/trials/insulin-aspart-vs-insulin-lispro-vs-regular-insulin-in-paediatric-population-6045https://curecurrent.com/trials/safety-and-efficacy-of-novolog-vs-humalog-in-insulin-pumps-in-children-and-adolescents-6046https://curecurrent.com/trials/safety-and-efficacy-of-insulin-aspart-vs-regular-human-insulin-in-gestational-diabetes-6047https://curecurrent.com/trials/drug-interaction-with-metformin-6048https://curecurrent.com/trials/evaluation-of-cardiovascular-outcomes-in-patients-with-type-2-diabetes-after-acute-coronary-syndrome-during-treatment-wi-6049https://curecurrent.com/trials/bigfoot-biomedical-clinical-research-center-crc-trial-6050https://curecurrent.com/trials/out-patient-study-in-patients-with-type-2-diabetes-mellitus-who-are-taking-no-diabetes-medication-or-metformin-only-6051https://curecurrent.com/trials/glp-1-receptor-agonist-lixisenatide-morning-or-evening-in-patients-with-type-2-diabetes-for-glycemic-control-and-safety-6052https://curecurrent.com/trials/dynamic-plantar-microvascular-skin-response-to-compressive-loads-in-at-risk-diabetic-and-healthy-control-a-pilot-study-6053https://curecurrent.com/trials/glp-1-receptor-agonist-lixisenatide-in-patients-with-type-2-diabetes-for-glycemic-control-and-safety-evaluation-on-top-o-6054https://curecurrent.com/trials/glp-1-receptor-agonist-lixisenatide-in-patients-with-type-2-diabetes-for-glycemic-control-and-safety-evaluation-on-top-o-6055https://curecurrent.com/trials/a-pychoeducational-intervention-for-women-with-diabetes-6056https://curecurrent.com/trials/glp-1-receptor-agonist-lixisenatide-in-patients-with-type-2-diabetes-for-glycemic-control-and-safety-evaluation-in-monot-6057https://curecurrent.com/trials/metabolomic-profiling-of-novel-mediators-of-vascular-function-6058https://curecurrent.com/trials/the-effects-of-apple-consumption-on-cardiovascular-health-in-prediabetics-and-type-2-diabetics-6059https://curecurrent.com/trials/tart-cherry-metabolic-syndrome-and-cardiovascular-risk-6060https://curecurrent.com/trials/comparison-of-nn5401-versus-insulin-glargine-both-combined-with-metformin-treatment-in-subjects-with-type-2-diabetes-6061https://curecurrent.com/trials/pharmacodynamic-study-of-the-effect-of-incb013739-on-insulin-sensitivity-in-obese-type-2-diabetic-subjects-6062https://curecurrent.com/trials/insulin-sensitivity-impaired-counterregulation-and-glucose-variability-6063https://curecurrent.com/trials/glp-1-receptor-agonist-lixisenatide-versus-exenatide-in-patients-with-type-2-diabetes-for-glycemic-control-and-safety-ev-6064https://curecurrent.com/trials/feasibility-of-a-partnered-approach-to-prevent-diabetes-6065https://curecurrent.com/trials/glp-1-receptor-agonist-lixisenatide-in-patients-with-type-2-diabetes-for-glycemic-control-and-safety-evaluation-on-top-o-6066https://curecurrent.com/trials/glp-1-receptor-agonist-lixisenatide-in-patients-with-type-2-diabetes-for-glycemic-control-and-safety-evaluation-on-top-o-6067https://curecurrent.com/trials/effect-of-manual-medicine-or-cognitive-behavioral-therapy-with-chronic-uncontrolled-diabetes-6068https://curecurrent.com/trials/a-type-2-diabetes-study-of-the-longer-term-glycemic-effect-of-avandamet-vs-metformin-6069https://curecurrent.com/trials/action-to-control-cardiovascular-risk-in-diabetes-accord-6070https://curecurrent.com/trials/overcoming-barriers-in-vision-care-utilization-of-african-americans-with-diabetes-6071https://curecurrent.com/trials/sleep-intervention-for-youth-with-type-1-diabetes-6072https://curecurrent.com/trials/impact-of-gastric-bypass-surgery-on-risk-of-cvd-in-type-2-diabetes-mellitus-6073https://curecurrent.com/trials/integrated-population-program-for-diabetic-kidney-disease-6074https://curecurrent.com/trials/efficacy-of-vildagliptin-100-mg-as-compared-to-placebo-as-add-on-to-metformin-in-patients-with-type-2-diabetes-6075https://curecurrent.com/trials/safety-and-efficacy-of-vildagliptin-vs-thiazolidinedione-as-add-on-therapy-to-metformin-in-patients-with-type-2-diabetes-6076https://curecurrent.com/trials/extension-to-a-study-on-the-efficacy-and-safety-of-vildagliptin-in-combination-with-insulin-in-patients-with-type-2-diab-6077https://curecurrent.com/trials/a-study-to-evaluate-the-effects-of-vildagliptin-on-the-insulin-response-to-glucose-in-subjects-with-pre-diabetes-6078https://curecurrent.com/trials/the-effect-of-linagliptin-on-mitochondrial-and-endothelial-function-6079https://curecurrent.com/trials/safety-and-tolerability-of-escalating-intravenous-doses-of-pf-05231023-in-adult-subjects-with-type-2-diabetes-6080https://curecurrent.com/trials/extension-to-a-study-on-the-efficacy-and-safety-of-vildagliptin-compared-to-metformin-in-drug-naive-patients-with-type-2-6081https://curecurrent.com/trials/the-role-of-pulsatile-insulin-secretion-a-study-investigating-the-effects-of-partial-pacreatectomy-on-glucose-metabolism-6082https://curecurrent.com/trials/a-trial-of-bms-512148-in-patients-with-type-2-diabetes-mellitus-6083https://curecurrent.com/trials/characterization-of-the-kinetics-of-renal-glucose-reabsorption-in-response-to-dapagliflozin-in-healthy-subjects-and-in-s-6084https://curecurrent.com/trials/study-of-subcutaneous-doses-of-hip2b-in-subjects-with-type-2-diabetes-mellitus-treated-with-metformin-6085https://curecurrent.com/trials/behavioral-economic-incentives-to-improve-glycemic-control-among-adolescents-and-young-adults-6086https://curecurrent.com/trials/comparing-visual-acuity-measurements-how-well-you-can-see-using-a-standard-etdrs-chart-a-handheld-etdrs-chart-6087https://curecurrent.com/trials/pilot-study-of-hippocampal-function-in-type-1-diabetes-mellitus-t1dm-6088https://curecurrent.com/trials/pilot-study-testing-feasibility-of-health-screening-at-farm-site-6089https://curecurrent.com/trials/bioequivalence-study-of-two-albiglutide-drug-products-in-healthy-adult-subjects-6090https://curecurrent.com/trials/efficacy-and-safety-study-of-arc-4558-for-management-of-pain-associated-with-painful-diabetic-neuropathy-6091https://curecurrent.com/trials/the-association-between-peri-operative-hyperglycemia-and-major-morbidity-and-mortality-6092https://curecurrent.com/trials/a-study-of-pf-05175157-in-healthy-volunteers-and-type-2-diabetic-patients-6093https://curecurrent.com/trials/a-study-of-taspoglutide-versus-sitagliptin-for-the-treatment-of-patients-with-type-2-diabetes-mellitus-inadequately-cont-6094https://curecurrent.com/trials/latinos-understanding-the-need-for-adherence-6095https://curecurrent.com/trials/an-examination-of-the-blood-pressure-lowering-ability-and-safety-of-olmesartan-medoxomil-in-patients-with-type-ii-diabet-6096https://curecurrent.com/trials/performance-of-an-investigational-blood-glucose-monitoring-system-in-a-clinical-setting-6097https://curecurrent.com/trials/a-new-glucose-meter-with-alternative-site-testing-6098https://curecurrent.com/trials/glycemic-control-brain-structure-and-cognition-in-youth-with-type-1-diabetes-t1dm-6099https://curecurrent.com/trials/a-drug-drug-interaction-study-of-gk-activator-2-and-glyburide-in-patients-with-type-2-diabetes-6100https://curecurrent.com/trials/a-study-on-the-potential-of-aleglitazar-to-reduce-cardiovascular-risk-in-patients-with-stable-cardiovascular-disease-and-6101https://curecurrent.com/trials/a-drug-drug-interaction-study-of-gk-activator-2-and-simvastatin-in-patients-with-type-2-diabetes-6102https://curecurrent.com/trials/a-study-of-gk-activator-2-in-patients-with-type-2-diabetes-mellitus-treated-with-a-stable-dose-of-metformin-6103https://curecurrent.com/trials/a-study-with-aleglitazar-in-patients-with-a-recent-acute-coronary-syndrome-and-type-2-diabetes-mellitus-6104https://curecurrent.com/trials/study-of-ro6807952-in-patients-with-diabetes-mellitus-type-2-6105https://curecurrent.com/trials/a-multiple-ascending-dose-study-of-ro4998452-in-patients-with-type-2-diabetes-mellitus-6106https://curecurrent.com/trials/a-safety-pharmacokinetics-and-pharmacodynamics-study-of-ro6811135-in-patients-with-type-2-diabetes-mellitus-6107https://curecurrent.com/trials/a-study-of-a-glp-1-analogue-in-patients-with-type-2-diabetes-treated-with-metformin-6108https://curecurrent.com/trials/a-study-of-dpp-iv-inhibitor-in-patients-with-type-2-diabetes-6109https://curecurrent.com/trials/a-study-of-aleglitazar-in-combination-with-metformin-in-patients-with-type-2-diabetes-mellitus-who-are-inadequately-cont-6110https://curecurrent.com/trials/a-study-of-dpp-iv-inhibitor-in-patients-with-type-2-diabetes-6111https://curecurrent.com/trials/a-study-of-aleglitazar-in-patients-with-type-2-diabetes-6112https://curecurrent.com/trials/a-pharmacodynamic-pharmacokinetic-study-of-aleglitazar-in-patients-with-type-2-diabetes-mellitus-on-treatment-with-lisin-6113https://curecurrent.com/trials/a-study-of-ro5095932-in-patients-with-type-2-diabetes-mellitus-6114https://curecurrent.com/trials/a-study-to-evaluate-the-long-term-safety-and-tolerability-of-gk-activator-2-in-patients-with-type-2-diabetes-6115https://curecurrent.com/trials/a-study-with-ro5095932-in-patients-with-type-2-diabetes-on-stable-metformin-therapy-6116https://curecurrent.com/trials/a-dose-titration-study-of-gk-activator-2-in-patients-with-type-2-diabetes-6117https://curecurrent.com/trials/a-study-of-taspoglutide-versus-exenatide-for-the-treatment-of-patients-with-type-2-diabetes-mellitus-inadequately-contro-6118https://curecurrent.com/trials/a-study-of-ro4998452-in-type-2-diabetes-patients-with-varying-degrees-of-renal-impairment-6119https://curecurrent.com/trials/a-study-of-ro6807952-in-patients-with-diabetes-mellitus-type-2-6120https://curecurrent.com/trials/a-study-of-gk-activator-2-in-patients-with-type-2-diabetes-mellitus-6121https://curecurrent.com/trials/a-study-of-the-effect-of-renal-impairment-on-the-activity-of-gk-activator-2-in-patients-with-type-2-diabetes-6122https://curecurrent.com/trials/a-study-of-taspoglutide-in-patients-with-inadequately-controlled-diabetes-mellitus-type-2-and-cardiovascular-disease-6123https://curecurrent.com/trials/a-titration-study-of-a-glucagon-like-peptide-1-glp-1-analogue-in-patients-with-type-2-diabetes-treated-with-metformin-6124https://curecurrent.com/trials/a-study-of-taspoglutide-versus-pioglitazone-in-patients-with-type-2-diabetes-6125https://curecurrent.com/trials/adult-accuracy-study-of-the-enlite-3-glucose-sensor-6126https://curecurrent.com/trials/connecting-smartphones-with-electronic-health-record-to-facilitate-behavioral-goal-monitoring-in-diabetes-care-6127https://curecurrent.com/trials/the-diabetes-medication-adherence-promotion-intervention-trial-6128https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-and-safety-of-the-addition-of-canagliflozin-in-participants-with-type-2-diabetes-mellit-6129https://curecurrent.com/trials/advancing-the-standard-of-care-for-pin-site-care-6130https://curecurrent.com/trials/bioequivalence-of-two-novolog-formulations-in-subjects-with-type-1-diabetes-6131https://curecurrent.com/trials/a-phase-iia-study-of-bms-512148-to-assess-safety-exposure-and-biological-effects-in-stable-type-2-diabetic-subjects-6132https://curecurrent.com/trials/aliskiren-hctz-compared-to-amlodipine-in-patients-with-stage-2-systolic-hypertension-and-diabetes-mellitus-6133https://curecurrent.com/trials/soy-supplementation-and-gestational-diabetes-6134https://curecurrent.com/trials/an-exercise-intervention-to-prevent-gestational-diabetes-6135https://curecurrent.com/trials/in-patient-study-with-gsk716155-in-patients-with-type-2-diabetes-mellitus-6136https://curecurrent.com/trials/milk-fat-intake-and-metabolic-health-markers-6137https://curecurrent.com/trials/bgat-blood-glucose-awareness-training-for-users-who-might-become-pregnant-6138https://curecurrent.com/trials/t-and-b-cell-responses-in-autoimmune-diseases-6139https://curecurrent.com/trials/characteristics-of-dendritic-cells-before-and-after-gastric-banding-6140https://curecurrent.com/trials/pilot-stair-climbing-study-6141https://curecurrent.com/trials/impact-of-a-diabetes-transitions-tool-kit-on-post-hospitalization-glycemic-control-6142https://curecurrent.com/trials/a-pilot-feasibility-study-of-fibroblast-calcium-and-glucoregulation-in-health-and-disease-6143https://curecurrent.com/trials/tracking-optical-coherence-tomography-6144https://curecurrent.com/trials/development-of-a-comprehensive-ap-training-curriculum-for-adults-6145https://curecurrent.com/trials/diet-and-metabolic-inflammation-6146https://curecurrent.com/trials/addition-of-exenatide-to-insulin-glargine-in-type-2-diabetes-mellitus-6147https://curecurrent.com/trials/effectiveness-of-autologel-therapy-in-diabetic-foot-ulcers-6148https://curecurrent.com/trials/effects-of-sitagliptin-on-endothelial-function-in-type-2-diabetes-on-background-metformin-therapy-6149https://curecurrent.com/trials/efficacy-of-autologel-therapy-to-usual-and-customary-care-in-wagner-gd-1-and-2-diabetic-foot-ulcers-6150https://curecurrent.com/trials/rosiglitazone-induced-weight-gain-6151https://curecurrent.com/trials/the-effect-of-real-time-continuous-glucose-monitoring-in-subjects-with-pre-diabetes-6152https://curecurrent.com/trials/randomized-trial-to-assess-efficacy-and-safety-of-continuous-glucose-monitoring-in-children-4-10-years-with-t1dm-6153https://curecurrent.com/trials/continuous-glucose-sensor-profiles-in-non-diabetic-subjects-6154https://curecurrent.com/trials/novofine-autocover-safety-needle-versus-bd-safety-glide-6155https://curecurrent.com/trials/minnesota-medicaid-incentives-to-prevent-chronic-disease-6156https://curecurrent.com/trials/a-study-of-the-treatment-of-type-2-diabetes-with-an-insulin-infusion-pump-6157https://curecurrent.com/trials/health-economic-assessment-of-lower-extremity-diabetic-healed-ulcers-with-primatrix-6158https://curecurrent.com/trials/renal-mechanism-of-action-splay-vs-tmg-6159https://curecurrent.com/trials/pharmacokinetic-drug-interaction-study-of-dapagliflozin-and-valsartan-or-simvastatin-in-healthy-subjects-6160https://curecurrent.com/trials/pharmacodynamics-pharmacokinetics-safety-and-tolerability-of-ultra-low-doses-of-dapagliflozin-in-healthy-subjects-6161https://curecurrent.com/trials/effect-of-rifampin-on-the-pharmacokinetics-of-dapagliflozin-in-healthy-subjects-6162https://curecurrent.com/trials/study-of-the-effect-of-dapagliflozin-on-the-pharmacokinetics-of-warfarin-or-digoxin-in-healthy-subjects-6163https://curecurrent.com/trials/renal-impairment-in-type-2-diabetic-subjects-6164https://curecurrent.com/trials/pharmacodynamic-effect-of-prasugrel-vs-ticagrelor-in-diabetes-6165https://curecurrent.com/trials/bioavailability-study-of-fixed-dose-combination-fdc-formulations-of-dapagliflozin-and-metformin-xr-versus-individual-com-6166https://curecurrent.com/trials/a-single-site-randomized-double-blind-placebo-controlled-trial-of-nic5-15-in-subjects-with-alzheimer-s-disease-6167https://curecurrent.com/trials/a-phase-2-multi-center-study-to-compare-the-efficacy-and-safety-of-a-chemokine-ccr2-5-receptor-antagonist-with-ranibizum-6168https://curecurrent.com/trials/study-of-the-absolute-oral-bioavailability-of-dapagliflozin-in-healthy-subjects-6169https://curecurrent.com/trials/pharmacokinetic-drug-interaction-study-of-dapagliflozin-and-glimepiride-or-sitagliptin-in-healthy-subjects-6170https://curecurrent.com/trials/study-to-evaluate-the-potential-pharmacokinetic-interaction-and-pharmacodynamic-effects-on-renal-parameters-of-bumetanid-6171https://curecurrent.com/trials/the-public-private-partnership-addressing-literacy-numeracy-to-improve-diabetes-care-6172https://curecurrent.com/trials/comparison-of-lixisenatide-injected-prior-to-the-main-meal-of-the-day-versus-prior-to-breakfast-in-type-2-diabetic-patie-6173https://curecurrent.com/trials/at-home-study-of-a-zone-model-predictive-control-mpc-controller-and-a-health-monitoring-system-hms-with-the-diabetes-ass-6174https://curecurrent.com/trials/glycemic-response-to-three-oral-nutrition-supplements-in-persons-with-type-2-diabetes-mellitus-6175https://curecurrent.com/trials/glycemic-response-to-two-enteral-formulas-in-persons-with-type-2-diabetes-mellitus-6176https://curecurrent.com/trials/24-week-treatment-with-lixisenatide-in-type-2-diabetes-insufficiently-controlled-with-metformin-and-insulin-glargine-6177https://curecurrent.com/trials/24-week-study-comparing-lixisenatide-to-sitagliptin-as-add-on-to-metformin-in-obese-type-2-diabetic-patients-younger-tha-6178https://curecurrent.com/trials/evaluation-of-biomarker-expression-in-diabetic-and-healthy-subjects-over-a-one-year-period-6179https://curecurrent.com/trials/fasiglifam-25-mg-bid-vs-50-mg-qd-6180https://curecurrent.com/trials/the-effect-of-pregabalin-on-pain-related-to-walking-in-patients-with-diabetic-peripheral-neuropathy-6181https://curecurrent.com/trials/protein-kinase-c-pkc-inhibitor-diabetic-retinopathy-phase-3-study-6182https://curecurrent.com/trials/multi-layer-insoles-for-a-patient-specific-approach-to-shear-and-pressure-reduction-in-diabetes-related-foot-ulcer-6183https://curecurrent.com/trials/effect-of-ruboxistaurin-on-clinically-significant-macular-edema-6184https://curecurrent.com/trials/treatment-for-completers-of-the-study-b7a-mc-mbcm-6185https://curecurrent.com/trials/reduction-in-the-occurrence-of-center-involved-diabetic-macular-edema-6186https://curecurrent.com/trials/diabetes-prevention-and-control-in-the-workplace-a-pilot-study-6187https://curecurrent.com/trials/feet-first-promoting-physical-activity-among-people-with-diabetes-mellitus-and-insensate-feet-6188https://curecurrent.com/trials/evaluation-of-the-dpp-4-inhibitor-sitagliptin-in-the-treatment-of-non-alcoholic-fatty-liver-disease-using-mri-6189https://curecurrent.com/trials/effects-of-colesevelam-hcl-rosiglitazone-sitagliptin-on-control-of-blood-glucose-and-lipids-in-type-2-diabetes-patients-6190https://curecurrent.com/trials/safety-tolerability-and-preliminary-efficacy-of-azd5213-in-combination-with-pregabalin-in-subjects-with-pdn-and-good-pai-6191https://curecurrent.com/trials/effects-of-febuxostat-on-adipokines-and-kidney-disease-in-diabetic-chronic-kidney-disease-6192https://curecurrent.com/trials/extended-work-schedules-sleep-loss-and-health-6193https://curecurrent.com/trials/integrating-targeted-medlineplus-health-prescriptions-into-clinic-practice-workflow-6194https://curecurrent.com/trials/effect-of-a-basal-pre-meal-insulin-strategy-detemir-aspart-on-insulin-secretion-and-action-in-type-2-diabetes-6195https://curecurrent.com/trials/adding-exenatide-to-insulin-therapy-for-patients-with-type-2-diabetes-and-non-alcoholic-fatty-liver-disease-6196https://curecurrent.com/trials/study-of-topical-ocular-pan-90806-in-pdr-6197https://curecurrent.com/trials/study-of-two-dosing-regimens-of-pf-04937319-compared-to-an-approved-agent-sitagliptin-in-patients-with-type-2-diabetes-6198https://curecurrent.com/trials/effect-of-reminders-on-adherence-6199https://curecurrent.com/trials/adult-subjects-with-uncontrolled-type-2-diabetes-6200https://curecurrent.com/trials/phase-2-study-to-evaluate-safety-efficacy-of-rm-131-administered-to-patients-with-diabetic-gastroparesis-6201https://curecurrent.com/trials/a-prospective-clinical-trial-of-the-tantalus-system-in-treatment-of-obese-to-morbidly-obese-patients-6202https://curecurrent.com/trials/study-to-assess-pharmacodynamics-of-rm-131-in-patients-with-diabetic-gastroparesis-6203https://curecurrent.com/trials/a-primary-care-ehr-based-strategy-to-promote-safe-and-appropriate-drug-use-6204https://curecurrent.com/trials/the-blossom-project-blossomup-methods-to-decrease-sedentary-time-in-pregnancy-6205https://curecurrent.com/trials/assessing-the-pk-and-effect-on-glucose-and-gi-hormone-concentrations-of-metformin-delayed-release-in-subjects-with-t2dm-6206https://curecurrent.com/trials/pharmacokinetic-single-dose-trial-of-empagliflozin-in-children-and-adolescents-with-type-2-diabetes-mellitus-6207https://curecurrent.com/trials/rosiglitazone-in-subjects-with-type-2-diabetes-mellitus-who-are-inadequately-controlled-on-insulin-6208https://curecurrent.com/trials/rosiglitazone-on-microalbuminuria-in-type-2-diabetics-6209https://curecurrent.com/trials/finding-a-safe-and-effective-dose-of-linagliptin-in-pediatric-patients-with-type-2-diabetes-6210https://curecurrent.com/trials/diabetic-treatment-adherence-6211https://curecurrent.com/trials/validation-of-an-rlip76-assay-in-humans-6212https://curecurrent.com/trials/inpatient-evaluation-of-an-automated-closed-loop-control-to-range-system-6213https://curecurrent.com/trials/pharmacokinetic-comparison-of-intradermal-versus-sub-cutaneous-insulin-and-glucagon-delivery-in-type-1-diabetes-6214https://curecurrent.com/trials/hormone-responses-during-hypoglycemia-and-the-accuracy-of-continuous-glucose-monitors-6215https://curecurrent.com/trials/pilot-study-of-the-navigator-continuous-glucose-monitor-6216https://curecurrent.com/trials/pilot-study-of-the-glucowatch-g2-biographer-for-the-management-of-type-1-diabetes-in-children-6217https://curecurrent.com/trials/study-to-determine-the-relationship-between-exercise-and-hypoglycemia-in-children-with-type-1-diabetes-6218https://curecurrent.com/trials/continuous-glucose-monitors-for-children-with-diabetes-mellitus-6219https://curecurrent.com/trials/the-effect-of-insulin-during-exercise-on-the-development-of-low-blood-sugar-in-individuals-with-type-i-diabetes-6220https://curecurrent.com/trials/effect-of-the-fat-content-of-the-bedtime-snack-on-overnight-hypoglycemia-6221https://curecurrent.com/trials/study-of-stress-hyperglycemia-as-an-indicator-of-diabetes-mellitus-6222https://curecurrent.com/trials/a-pilot-study-to-evaluate-the-safety-of-terbutaline-in-children-with-type-1-diabetes-6223https://curecurrent.com/trials/randomized-clinical-trial-to-assess-the-effectiveness-of-the-glucowatch-biographer-6224https://curecurrent.com/trials/assessing-continuous-glucose-monitors-in-healthy-children-6225https://curecurrent.com/trials/efficacy-and-safety-of-empagliflozin-bi-10773-with-metformin-in-patients-with-type-2-diabetes-6226https://curecurrent.com/trials/tandem-predictive-low-glucose-suspend-inpatient-feasibility-study-6227https://curecurrent.com/trials/tak-648-multiple-rising-dose-study-in-healthy-japanese-participants-and-non-japanese-participants-with-type-2-diabetes-m-6228https://curecurrent.com/trials/a-novel-positron-emission-tomography-pet-approach-to-measuring-myocardial-metabolism-6229https://curecurrent.com/trials/outpatient-pump-shutoff-pilot-feasibility-and-efficacy-study-6230https://curecurrent.com/trials/outpatient-reduction-of-nocturnal-hypoglycemia-by-using-predictive-algorithms-and-pump-suspension-in-children-6231https://curecurrent.com/trials/an-outpatient-pump-shutoff-pilot-feasibility-and-safety-study-6232https://curecurrent.com/trials/pharmacokinetic-study-of-cycloset-0-8-mg-tablets-in-children-and-adolescent-type-2-diabetes-mellitus-subjects-6233https://curecurrent.com/trials/laser-ranibizumab-triamcinolone-for-proliferative-diabetic-retinopathy-6234https://curecurrent.com/trials/a-phase-2-evaluation-of-anti-vegf-therapy-for-diabetic-macular-edema-bevacizumab-avastin-6235https://curecurrent.com/trials/effect-of-diabetes-education-during-retinal-ophthalmology-visits-on-diabetes-control-6236https://curecurrent.com/trials/the-course-of-response-to-focal-photocoagulation-for-dme-6237https://curecurrent.com/trials/way-to-health-healthy-measures-6238https://curecurrent.com/trials/study-of-ro-205-2349-in-patients-with-type-2-diabetes-mellitus-6239https://curecurrent.com/trials/a-study-to-evaluate-safety-pharmacokinetics-and-pharmacodynamics-of-escalating-doses-of-sar438544-in-comparison-to-place-6240https://curecurrent.com/trials/surgery-or-lifestyle-intervention-for-type-2-diabetes-solid-6241https://curecurrent.com/trials/insulin-resistance-in-the-control-of-intestinal-lipid-metabolism-6242https://curecurrent.com/trials/lisofylline-as-continuous-subcutaneous-and-intravenous-administration-in-subjects-with-type-1-diabetes-mellitus-6243https://curecurrent.com/trials/relationship-between-changes-in-gut-hormones-after-gastric-bypass-and-gastric-banding-and-improvements-in-diabetes-6244https://curecurrent.com/trials/immunobiology-of-diabetes-and-tuberculosis-6245https://curecurrent.com/trials/study-of-amniotic-membrane-graft-in-the-management-of-diabetic-foot-ulcers-6246https://curecurrent.com/trials/leptin-to-treat-lipodystrophy-6247https://curecurrent.com/trials/telehealth-intervention-for-youth-with-t1dm-6248https://curecurrent.com/trials/evaluating-cvd-medication-adherence-program-in-low-ses-6249https://curecurrent.com/trials/a-study-of-aleglitazar-in-patients-with-type-2-diabetes-mellitus-who-have-not-previously-received-anti-hyperglycemic-the-6250https://curecurrent.com/trials/actos-now-for-prevention-of-diabetes-act-now-6251https://curecurrent.com/trials/hormones-and-sexual-function-predict-outcomes-in-revascularized-men-with-diabetes-6252https://curecurrent.com/trials/effect-pulsatile-iv-insulin-therapy-on-the-quality-of-life-in-patients-with-types-1-and-2-diabetes-6253https://curecurrent.com/trials/effects-of-pulsatile-intravenous-insulin-delivery-on-diabetic-neuropathy-in-patients-pts-with-type-1-and-type-2-diabetes-6254https://curecurrent.com/trials/a-prospective-collection-of-peripheral-blood-and-urine-specimens-to-study-c-peptide-and-insulin-in-healthy-individuals-6255https://curecurrent.com/trials/effects-of-pulsatile-iv-insulin-delivery-on-diabetic-retinopathy-in-patients-with-types-1-and-2-diabetes-mellitus-6256https://curecurrent.com/trials/effects-of-pulsatile-insulin-delivery-on-diabetic-neuropathy-in-patients-with-types-1-and-2-diabetes-mellitus-6257https://curecurrent.com/trials/effects-of-pulsatile-intravenous-insulin-therapy-on-metabolic-integrity-in-patients-with-diabetes-mellitus-6258https://curecurrent.com/trials/effects-of-pulsatile-intravenous-iv-insulin-on-wound-healing-in-diabetics-6259https://curecurrent.com/trials/effects-of-pulsatile-intravenous-insulin-therapy-on-cardiac-disease-in-patients-with-diabetes-6260https://curecurrent.com/trials/effects-of-pulsatile-intravenous-insulin-delivery-on-hypoglycemic-unawareness-6261https://curecurrent.com/trials/clinical-effects-of-pulsatile-insulin-delivery-on-cognitive-function-phase-1-6262https://curecurrent.com/trials/effects-of-krill-oil-on-endothelial-function-in-patients-with-type-2-diabetes-mellitus-6263https://curecurrent.com/trials/medtable-an-electronic-medical-record-emr-strategy-to-promote-patient-medication-understanding-and-use-6264https://curecurrent.com/trials/glycaemic-control-of-monthly-laps-exendin-versus-placebo-in-subjects-of-type-2-diabetes-6265https://curecurrent.com/trials/glycaemic-control-of-weekly-laps-exendin-versus-placebo-in-subjects-of-type-2-diabetes-6266https://curecurrent.com/trials/effect-of-laps-exendin-on-body-weight-in-obese-population-6267https://curecurrent.com/trials/the-effect-of-renin-inhibition-on-nerve-function-in-diabetes-6268https://curecurrent.com/trials/effect-of-pulsatile-iv-insulin-on-circulating-risk-markers-of-vascular-and-metabolic-complications-in-pts-with-diabetes-6269https://curecurrent.com/trials/safety-tolerability-pharmacokinetics-pharmacodynamics-study-of-laps-exendin-in-subjects-of-type-2-diabetes-mellitus-6270https://curecurrent.com/trials/diabetes-go-mobile-pilot-study-6271https://curecurrent.com/trials/the-inova-type-2-diabetes-mellitus-study-6272https://curecurrent.com/trials/a-study-of-dipeptidyl-peptidase-iv-dpp-iv-ro4876904-in-patients-with-type-2-diabetes-6273https://curecurrent.com/trials/a-study-of-taspoglutide-versus-placebo-for-the-treatment-of-patients-with-type-2-diabetes-mellitus-inadequately-controll-6274https://curecurrent.com/trials/a-comparative-study-of-aleglitazar-and-actos-in-patients-with-type-2-diabetes-mellitus-and-new-york-heart-association-ny-6275https://curecurrent.com/trials/a-comparison-of-the-effects-of-aleglitazar-and-actos-on-renal-function-on-patients-with-type-2-diabetes-6276https://curecurrent.com/trials/identifying-genes-that-may-increase-the-risk-for-heart-disease-in-african-americans-6277https://curecurrent.com/trials/an-intervention-trial-for-cardiac-neuropathy-in-type-1-diabetes-6278https://curecurrent.com/trials/a-study-of-the-safety-tolerability-and-effect-on-glycemic-control-of-taspoglutide-versus-insulin-glargine-in-insulin-nai-6279https://curecurrent.com/trials/a-study-of-ro5093151-and-ro5027838-in-patients-with-type-2-diabetes-mellitus-on-a-stable-dose-of-metformin-6280https://curecurrent.com/trials/a-study-of-taspoglutide-versus-placebo-for-the-treatment-of-patients-with-type-2-diabetes-mellitus-inadequately-controll-6281https://curecurrent.com/trials/l-arginine-vascular-response-and-mechanisms-6282https://curecurrent.com/trials/a-study-of-taspoglutide-versus-placebo-for-the-treatment-of-obese-patients-with-type-2-diabetes-mellitus-inadequately-co-6283https://curecurrent.com/trials/islet-transplantation-using-abatacept-6284https://curecurrent.com/trials/effect-of-ly333531-on-vascular-and-neural-functions-6285https://curecurrent.com/trials/isoprostane-fmd-study-the-effect-of-protein-kinase-c-pkc-specific-inhibitor-ly333531-on-oxidant-stress-in-patients-with-6286https://curecurrent.com/trials/a-pilot-study-using-weightloss-and-exercise-to-prevent-recurring-gestational-diabetes-in-obese-women-6287https://curecurrent.com/trials/treatment-for-symptomatic-peripheral-neuropathy-in-patients-with-diabetes-6288https://curecurrent.com/trials/the-effect-of-ruboxistaurin-on-small-fiber-function-6289https://curecurrent.com/trials/training-pain-connoisseurs-for-efficient-analgesic-proof-of-concept-studies-6290https://curecurrent.com/trials/feasibility-study-of-pid-versus-mpc-and-hms-6291https://curecurrent.com/trials/mpc-versus-pid-for-closed-loop-insulin-delivery-6292https://curecurrent.com/trials/effects-of-ppar-ligands-on-ectopic-fat-accumulation-and-inflammation-6293https://curecurrent.com/trials/ability-to-cope-with-type-1-diabetes-6294https://curecurrent.com/trials/a-survey-to-elicit-the-relationship-between-literacy-and-glycemic-control-in-pediatric-diabetes-6295https://curecurrent.com/trials/bmi-and-its-relationship-to-hypoglycemic-seizures-in-children-with-insulin-requiring-diabetes-6296https://curecurrent.com/trials/disaster-preparedness-among-families-caring-for-children-with-diabetes-6297https://curecurrent.com/trials/full-day-and-night-closed-loop-with-dias-platform-6298https://curecurrent.com/trials/a-study-of-effects-of-canagliflozin-as-add-on-therapy-to-insulin-in-the-treatment-of-participants-with-type-1-diabetes-m-6299https://curecurrent.com/trials/islet-transplantation-in-type-1-diabetics-using-the-edmonton-protocol-of-steroid-free-immunosuppression-6300https://curecurrent.com/trials/ability-to-cope-with-type-1-diabetes-6301https://curecurrent.com/trials/lantus-in-the-treatment-of-type-1-diabetes-children-6302https://curecurrent.com/trials/continuous-subcutaneous-infusion-of-pramlintide-and-insulin-6303https://curecurrent.com/trials/the-role-of-amylin-and-glucagon-in-t1dm-6304https://curecurrent.com/trials/the-effect-of-prolonged-pramlintide-infusion-in-pediatric-diabetes-6305https://curecurrent.com/trials/safety-and-efficacy-of-dextromethorphan-and-quinidine-in-the-treatment-of-the-pain-of-diabetic-neuropathy-6306https://curecurrent.com/trials/gestational-diabetes-and-sleep-disordered-breathing-6307https://curecurrent.com/trials/lunch-time-insulin-injection-by-school-nurse-for-poorly-controlled-diabetes-6308https://curecurrent.com/trials/evaluation-of-a-nutritional-supplement-for-people-with-type-2-diabetes-6309https://curecurrent.com/trials/evaluating-the-impact-of-year-long-augmented-diabetes-self-management-support-6310https://curecurrent.com/trials/improving-neurologic-outcomes-in-people-with-diabetes-who-are-undergoing-heart-surgery-6311https://curecurrent.com/trials/study-of-dapagliflozin-in-combination-with-metformin-xr-to-initiate-the-treatment-of-type-2-diabetes-6312https://curecurrent.com/trials/loop-duodenal-switch-surgery-in-morbidly-obese-patients-6313https://curecurrent.com/trials/study-of-the-acute-metabolic-effect-of-exenatide-in-type-1-diabetes-6314https://curecurrent.com/trials/effect-of-amount-and-type-of-dietary-carbohydrates-on-risk-for-cardiovascular-heart-disease-and-diabetes-6315https://curecurrent.com/trials/safety-tolerability-and-efficacy-of-isis-gcgrrx-in-type-2-diabetes-6316https://curecurrent.com/trials/evaluation-of-group-lifestyle-balance-dvd-in-primary-care-practice-6317https://curecurrent.com/trials/n-acetylcysteine-and-milk-thistle-for-treatment-of-diabetic-nephropathy-6318https://curecurrent.com/trials/implementation-of-a-population-health-chronic-disease-management-program-6319https://curecurrent.com/trials/evaluation-of-group-lifestyle-balance-maintenance-strategies-6320https://curecurrent.com/trials/a-performance-evaluation-of-the-enlite-3-sensor-6321https://curecurrent.com/trials/a-phase-i-study-to-assess-the-pharmacodynamics-of-oral-ar-c165395xx-in-subjects-with-type-2-diabetes-mellitus-t2dm-6322https://curecurrent.com/trials/mild-compression-sock-for-control-of-lower-extremity-edema-in-individuals-with-diabetes-6323https://curecurrent.com/trials/efficacy-of-syr-472-in-subjects-with-type-2-diabetes-mellitus-6324https://curecurrent.com/trials/safety-and-efficacy-of-dapagliflozin-in-triple-therapy-to-treat-subjects-with-type-2-diabetes-6325https://curecurrent.com/trials/efficacy-and-safety-of-syr-472-in-subjects-with-type-2-diabetes-mellitus-6326https://curecurrent.com/trials/does-pioglitazone-increase-the-production-of-15-epi-lipoxin-a4-6327https://curecurrent.com/trials/efficacy-and-safety-of-tak-583-in-subjects-with-diabetic-peripheral-neuropathy-6328https://curecurrent.com/trials/study-of-the-use-of-niaspan-for-treatment-of-dyslipidemia-in-diabetic-nephropathy-6329https://curecurrent.com/trials/efficacy-and-safety-of-tak-379-in-adult-subjects-with-type-2-diabetes-mellitus-6330https://curecurrent.com/trials/the-metabolic-effects-of-almond-consumption-in-adults-with-pre-diabetes-6331https://curecurrent.com/trials/lay-user-trial-of-the-iglucose-blood-glucose-monitoring-system-6332https://curecurrent.com/trials/southeastern-diabetes-initiative-clinical-intervention-6333https://curecurrent.com/trials/effect-of-the-anti-oxidant-n-acetylcysteine-on-beta-cell-function-in-type-2-diabetes-6334https://curecurrent.com/trials/safety-tolerability-pharmacokinetics-and-pharmacodynamics-study-of-pf-06291874-as-oral-monotherapy-to-treat-adults-with-6335https://curecurrent.com/trials/study-of-the-relationship-between-blood-vessels-and-insulin-response-in-adolescents-6336https://curecurrent.com/trials/insulin-treatment-variation-in-southwestern-diabetics-6337https://curecurrent.com/trials/artificial-pancreas-control-system-in-an-inpatient-setting-6338https://curecurrent.com/trials/a-study-of-effectiveness-and-safety-of-jnj-42160443-in-patients-with-diabetic-painful-neuropathy-6339https://curecurrent.com/trials/comparison-of-fasiglifam-tak-875-to-placebo-and-sitagliptin-in-combination-with-metformin-in-participants-with-type-2-di-6340https://curecurrent.com/trials/pet-ownership-and-glucose-control-in-type-1-diabetes-6341https://curecurrent.com/trials/improving-metabolic-assessments-in-type-1-diabetes-mellitus-clinical-trials-6342https://curecurrent.com/trials/a-study-to-evaluate-itca-650-compared-to-sitagliptin-as-add-on-therapy-for-the-treatment-of-type-2-diabetes-6343https://curecurrent.com/trials/comparison-of-tak-875-to-placebo-as-an-add-on-to-glimepiride-in-patients-with-type-2-diabetes-6344https://curecurrent.com/trials/tak-875-fasiglifam-in-combination-with-sitagliptin-in-adults-with-type-2-diabetes-6345https://curecurrent.com/trials/efficacy-and-safety-of-tak-875-compared-to-glimepiride-when-used-with-metformin-in-participants-with-type-2-diabetes-6346https://curecurrent.com/trials/resistance-to-antibiotics-in-patients-receiving-eye-injections-6347https://curecurrent.com/trials/squalamine-lactate-eye-drops-in-combination-with-ranibizumab-in-patients-with-diabetic-macular-edema-dme-6348https://curecurrent.com/trials/study-of-intravitreal-aflibercept-injection-iai-eylea-bay86-5321-in-patients-with-diabetic-macular-edema-6349https://curecurrent.com/trials/reach-detroit-partnership-family-intervention-6350https://curecurrent.com/trials/open-label-extension-study-to-evaluate-long-term-safety-and-treatment-effect-of-diapep277-6351https://curecurrent.com/trials/efficacy-and-safety-of-m100907-on-sleep-maintenance-insomnia-with-a-sub-study-in-stable-type-ii-diabetes-mellitus-6352https://curecurrent.com/trials/efficacy-and-safety-study-of-diapep277-in-newly-diagnosed-type-1-diabetes-adults-6353https://curecurrent.com/trials/efficacy-an-safety-of-volinanserin-on-sleep-maintenance-insomnia-with-a-sub-study-on-stable-type-ii-diabetes-mellitus-6354https://curecurrent.com/trials/omt-of-somatic-dysfunction-and-chronic-low-back-pain-in-patients-with-type-2-diabetes-mellitus-6355https://curecurrent.com/trials/exenatide-pregnancy-registry-type-2-diabetes-in-pregnancy-6356https://curecurrent.com/trials/use-of-decision-aids-in-clinical-encounters-6357https://curecurrent.com/trials/effects-of-a-high-protein-diet-on-clinical-outcomes-in-heart-failure-6358https://curecurrent.com/trials/comparison-of-the-ability-of-glulisine-with-lispro-to-control-type-1-diabetes-mellitus-in-children-and-adolescents-6359https://curecurrent.com/trials/defective-atypical-protein-kinase-c-pkc-activation-in-diabetes-and-metabolic-syndrome-6360https://curecurrent.com/trials/assessment-of-the-safety-of-sar342434-and-humalog-when-administered-as-continuous-subcutaneous-insulin-infusion-6361https://curecurrent.com/trials/exploring-the-effectiveness-of-sensor-based-balance-training-on-patient-outcome-measures-6362https://curecurrent.com/trials/correlation-of-continuous-glucose-monitoring-and-glucose-tolerance-testing-with-pregnancy-outcomes-6363https://curecurrent.com/trials/an-efficacy-and-safety-study-of-rimonabant-for-treatment-of-nonalcoholic-steatohepatitis-nash-in-patients-with-type-2-di-6364https://curecurrent.com/trials/a-comparison-study-of-the-bioavailability-of-a-capsule-formulation-of-lgd-6972-to-an-oral-solution-formulation-6365https://curecurrent.com/trials/rimonabant-in-prediabetic-subjects-to-delay-onset-of-type-2-diabetes-6366https://curecurrent.com/trials/glycemic-impact-of-myo-inositol-in-pregnancy-6367https://curecurrent.com/trials/an-efficacy-and-safety-study-of-rimonabant-for-treatment-of-nonalcoholic-steatohepatitis-nash-in-patients-without-diabet-6368https://curecurrent.com/trials/effect-of-rimonabant-and-metformin-combination-on-glycemic-control-in-patients-with-type-2-diabetes-6369https://curecurrent.com/trials/participatory-design-of-patient-centered-depression-and-diabetes-care-6370https://curecurrent.com/trials/the-use-of-bioscaffolds-in-conjunction-with-negative-pressure-therapy-a-prospective-randomized-double-blinded-trial-6371https://curecurrent.com/trials/study-of-rimonabant-metformin-combinations-to-investigate-diabetes-blood-sugar-control-in-patients-with-type-2-diabetes-6372https://curecurrent.com/trials/effects-of-tnf-alpha-antagonism-etanercept-in-patients-with-the-metabolic-syndrome-and-psoriasis-6373https://curecurrent.com/trials/effect-of-exenatide-on-liver-and-heart-fat-and-inflammation-6374https://curecurrent.com/trials/bi-10773-empagliflozin-cardiovascular-outcome-event-trial-in-type-2-diabetes-mellitus-patients-empa-reg-outcome-6375https://curecurrent.com/trials/a-glycemic-control-evaluation-of-glimepiride-versus-rimonabant-on-top-of-metformin-in-type-2-diabetes-6376https://curecurrent.com/trials/do-patient-centric-mhealth-programs-improve-patient-engagement-and-health-outcomes-6377https://curecurrent.com/trials/t-cell-validation-study-using-blood-samples-from-subjects-with-recent-onset-type-1-diabetes-mellitus-6378https://curecurrent.com/trials/soybean-oil-trial-of-cardiovascular-risk-6379https://curecurrent.com/trials/impact-of-sleep-and-meal-timing-on-food-intake-regulation-6380https://curecurrent.com/trials/study-of-regn1193-in-patients-with-type-2-diabetes-mellitus-6381https://curecurrent.com/trials/v2-receptor-effects-on-fluid-regulation-and-performance-6382https://curecurrent.com/trials/pgc-1-muscle-mitochondrial-dysfunction-in-diabetes-6383https://curecurrent.com/trials/mobile-application-to-enhance-diabetic-care-6384https://curecurrent.com/trials/glycemic-profile-in-women-with-gestational-diabetes-treated-with-glyburide-6385https://curecurrent.com/trials/shared-decision-making-with-pharmaceutical-care-6386https://curecurrent.com/trials/a-comparison-study-of-prototype-continuous-glucose-sensors-in-the-intradermal-and-subcutaneous-spaces-6387https://curecurrent.com/trials/beneficial-effect-of-salicylates-insulin-action-secretion-or-clearance-6388https://curecurrent.com/trials/effect-of-single-dose-pf-05175157-on-metabolic-and-cardiopulmonary-parameters-6389https://curecurrent.com/trials/a-6-week-study-to-determine-the-safety-and-effect-of-an-investigational-drug-given-with-canagliflozin-in-adults-with-typ-6390https://curecurrent.com/trials/a-6-week-study-to-determine-the-safety-and-effect-of-an-investigational-drug-on-adults-with-type-2-diabetes-mellitus-tak-6391https://curecurrent.com/trials/early-phase-pre-clinical-and-initial-clinical-research-on-epicatechin-part-2-6392https://curecurrent.com/trials/the-effects-of-micronutrients-in-combination-with-usual-care-in-type-2-diabetes-6393https://curecurrent.com/trials/move-out-a-partnership-with-veterans-groups-to-enhance-weight-management-in-the-veterans-health-administration-vha-6394https://curecurrent.com/trials/relationship-between-gastric-emptying-and-glycemic-variability-in-type-1-diabetes-mellitus-6395https://curecurrent.com/trials/strategies-to-improve-islet-survival-6396https://curecurrent.com/trials/diabetes-prevention-strategies-in-women-with-gestational-diabetes-mellitus-gdm-6397https://curecurrent.com/trials/ranibizumab-0-5mg-and-2-0mg-to-treat-diabetic-macular-edema-in-patients-with-poor-response-to-bevacizumab-6398https://curecurrent.com/trials/safety-and-efficacy-of-saxagliptin-in-triple-therapy-to-treat-subjects-with-type-2-diabetes-6399https://curecurrent.com/trials/outpatient-control-to-range-system-and-monitoring-testing-6400https://curecurrent.com/trials/peer-supported-diabetes-self-management-support-6401https://curecurrent.com/trials/activator-and-type-ii-diabetics-6402https://curecurrent.com/trials/doctors-and-web-based-self-management-support-pilot-study-6403https://curecurrent.com/trials/spanish-diabetes-self-management-program-6404https://curecurrent.com/trials/expressive-writing-for-reducing-stress-and-diabetic-symptoms-in-diabetes-patients-6405https://curecurrent.com/trials/effect-of-the-insupatch-on-automated-closed-loop-glucose-control-in-type-1-diabetes-6406https://curecurrent.com/trials/neuropsychological-and-neuroanatomical-studies-of-young-children-with-and-without-type-1-diabetes-mellitus-6407https://curecurrent.com/trials/continuous-glucose-monitor-use-in-school-6408https://curecurrent.com/trials/the-effects-of-high-and-low-blood-glucose-values-on-the-brain-in-children-with-type-1-diabetes-mellitus-6409https://curecurrent.com/trials/g5-mobile-continuous-glucose-monitoring-system-automated-vs-manual-sensor-applicator-6410https://curecurrent.com/trials/boosting-emotions-happiness-in-outpatients-living-with-diabetes-6411https://curecurrent.com/trials/matrix-metalloproteinases-and-diabetic-nephropathy-6412https://curecurrent.com/trials/efficacy-and-safety-of-tak-875-in-subjects-with-type-2-diabetes-mellitus-6413https://curecurrent.com/trials/effect-of-exenatide-treatment-on-liver-fat-content-in-patients-with-diabetes-6414https://curecurrent.com/trials/improving-diabetes-care-collaboratively-in-the-community-6415https://curecurrent.com/trials/early-feasibility-study-of-zone-mpc-and-hms-with-dias-in-the-outpatient-setting-6416https://curecurrent.com/trials/chromium-and-insulin-action-6417https://curecurrent.com/trials/assessing-the-effectiveness-of-a-weight-watchers-based-lifestyle-intervention-for-the-primary-prevention-of-type-2-diabe-6418https://curecurrent.com/trials/effect-of-chromium-picolinate-on-insulin-sensitivity-in-type-2-diabetes-6419https://curecurrent.com/trials/a-study-evaluating-safety-and-efficacy-of-biod-531-compared-to-humalog-mix-75-25-in-subjects-with-type-2-diabetes-6420https://curecurrent.com/trials/lea29y-belatacept-emory-edmonton-protocol-6421https://curecurrent.com/trials/healthy-lifestyles-for-mentally-ill-people-who-have-experienced-weight-gain-from-their-antipsychotic-medications-6422https://curecurrent.com/trials/exposure-to-type-ii-diabetes-for-two-siblings-with-the-same-parents-6423https://curecurrent.com/trials/comparison-of-tak-875-fasiglifam-with-placebo-in-participants-with-type-2-diabetes-6424https://curecurrent.com/trials/linagliptin-as-add-on-therapy-to-empagliflozin-10-mg-or-25-mg-with-background-metformin-in-patient-with-type-2-diabetes-6425https://curecurrent.com/trials/efficacy-and-safety-of-tak-875-in-combination-with-sitagliptin-in-participants-with-type-2-diabetes-mellitus-6426https://curecurrent.com/trials/the-effectiveness-of-resistance-training-on-glycemic-control-for-patients-with-type-2-diabetes-in-cardiac-rehabilitation-6427https://curecurrent.com/trials/mechanisms-of-glycemic-improvement-after-gastrointestinal-surgery-6428https://curecurrent.com/trials/calorie-reduction-or-surgery-seeking-remission-for-obesity-and-diabetes-6429https://curecurrent.com/trials/a-study-of-the-impact-of-genetic-testing-on-clinical-decision-making-and-patient-care-6430https://curecurrent.com/trials/effect-of-formoterol-on-the-counterregulatory-hormonal-response-to-hypoglycemia-in-type-1-diabetes-6431https://curecurrent.com/trials/reproducibility-and-method-comparison-studies-of-the-quo-test-a1c-system-and-the-quo-lab-a1c-test-and-clia-waiver-study-6432https://curecurrent.com/trials/physiologic-response-to-glucagon-at-varying-insulin-levels-6433https://curecurrent.com/trials/a-study-of-insulin-peglispro-ly2605541-in-participants-with-type-2-diabetes-mellitus-6434https://curecurrent.com/trials/patient-and-provider-glucose-reporting-preferences-ambulatory-glucose-profile-agp-6435https://curecurrent.com/trials/b-lymphocyte-immunotherapy-in-islet-transplantation-6436https://curecurrent.com/trials/walnut-consumption-endothelial-function-and-biomarkers-6437https://curecurrent.com/trials/apt001-plasma-no-generator-to-treat-diabetic-foot-ulcer-in-adults-6438https://curecurrent.com/trials/peritransplant-deoxyspergualin-in-islet-transplantation-in-type-1-diabetes-6439https://curecurrent.com/trials/the-effectiveness-of-lubiprostone-in-constipated-diabetics-6440https://curecurrent.com/trials/pharmacodynamic-evaluation-of-pl2200-versus-enteric-coated-and-immediate-release-aspirin-in-diabetic-patients-6441https://curecurrent.com/trials/implementation-of-a-patient-centered-self-management-program-for-patients-with-type-2-diabetes-6442https://curecurrent.com/trials/pharmacodynamic-evaluation-of-pl2200-versus-enteric-coated-aspirin-in-diabetic-patients-6443https://curecurrent.com/trials/pyridorin-in-diabetic-nephropathy-6444https://curecurrent.com/trials/the-comparative-effectiveness-of-telemedicine-to-detect-diabetic-retinopathy-6445https://curecurrent.com/trials/adjunctive-metformin-therapy-in-double-diabetes-6446https://curecurrent.com/trials/study-to-compare-single-dose-of-three-modified-release-formulations-of-pf-04937319-with-immediate-release-material-spari-6447https://curecurrent.com/trials/a-randomized-comparison-of-amnioclear-human-allograft-amniotic-membrane-vs-moist-wound-dressing-in-the-treatment-of-diab-6448https://curecurrent.com/trials/long-term-effects-of-diabetes-of-very-young-children-6449https://curecurrent.com/trials/glucose-meter-study-6450https://curecurrent.com/trials/performance-evaluation-of-an-investigational-blood-glucose-monitoring-system-6451https://curecurrent.com/trials/evaluation-of-labeling-comprehension-and-performance-of-a-new-blood-glucose-meter-system-6452https://curecurrent.com/trials/user-performance-evaluation-of-an-investigational-blood-glucose-monitoring-system-6453https://curecurrent.com/trials/evaluation-of-an-karajishi-contour-investigational-blood-glucose-monitoring-system-6454https://curecurrent.com/trials/comparison-evaluation-of-blood-glucose-meter-systems-in-a-clinical-setting-6455https://curecurrent.com/trials/evaluation-of-a-diabetes-data-management-system-6456https://curecurrent.com/trials/in-clinic-and-home-use-study-of-a-new-blood-glucose-monitoring-system-6457https://curecurrent.com/trials/evaluation-of-glucofacts-deluxe-diabetes-management-system-6458https://curecurrent.com/trials/study-of-an-investigational-glucose-meter-system-6459https://curecurrent.com/trials/evaluation-of-an-karajishi-ts-investigational-blood-glucose-monitoring-system-6460https://curecurrent.com/trials/study-of-an-investigational-glucose-meter-system-6461https://curecurrent.com/trials/comparison-evaluation-of-blood-glucose-meter-systems-6462https://curecurrent.com/trials/evaluation-of-blood-glucose-meter-systems-6463https://curecurrent.com/trials/performance-of-an-investigational-blood-glucose-monitoring-system-6464https://curecurrent.com/trials/evaluation-of-a-new-blood-glucose-meter-system-with-capillary-and-venous-blood-6465https://curecurrent.com/trials/evaluation-of-blood-glucose-monitoring-systems-6466https://curecurrent.com/trials/user-study-of-an-investigational-blood-glucose-monitoring-system-6467https://curecurrent.com/trials/performance-of-a-new-glucose-meter-system-in-children-and-young-adults-6468https://curecurrent.com/trials/evaluation-of-the-a1cnow-test-kit-6469https://curecurrent.com/trials/performance-evaluation-of-blood-glucose-monitoring-system-using-iso-study-design-6470https://curecurrent.com/trials/performance-of-an-investigational-blood-glucose-monitoring-system-in-a-clinical-trial-6471https://curecurrent.com/trials/performance-of-a-new-glucose-meter-system-6472https://curecurrent.com/trials/performance-of-an-investigational-blood-glucose-monitoring-system-in-a-clinical-setting-6473https://curecurrent.com/trials/evaluation-of-an-karajishi-contour-investigational-blood-glucose-monitoring-system-iso-fda-study-6474https://curecurrent.com/trials/the-health-outcomes-management-and-evaluation-home-study-6475https://curecurrent.com/trials/reducing-risk-of-type-2-diabetes-hydroxychloroquine-use-in-pre-diabetes-6476https://curecurrent.com/trials/12-week-efficacy-and-safety-study-of-empagliflozin-bi-10773-in-hypertensive-patients-with-type-2-diabetes-mellitus-6477https://curecurrent.com/trials/safety-and-efficacy-study-of-empagliflozin-and-metformin-for-24-weeks-in-treatment-naive-patients-with-type-2-diabetes-6478https://curecurrent.com/trials/develop-and-validate-a-self-administered-instrument-that-will-screen-for-eating-disorder-symptoms-in-persons-aged-12-and-6479https://curecurrent.com/trials/personalized-decision-support-for-older-patients-with-diabetes-6480https://curecurrent.com/trials/evaluating-electrocardiogram-ecg-abnormalities-from-young-adulthood-through-middle-age-6481https://curecurrent.com/trials/effect-of-naltrexone-on-counterregulatory-mechanisms-in-hypoglycemia-6482https://curecurrent.com/trials/a-trial-comparing-the-efficacy-of-insulin-degludec-with-insulin-glargine-on-glycaemic-control-using-continuous-glucose-m-6483https://curecurrent.com/trials/modulation-of-human-myocardial-metabolism-by-glp-1-dose-response-6484https://curecurrent.com/trials/drug-drug-interaction-study-of-glucokinase-activator-hms5552-and-metformin-in-t2dm-6485https://curecurrent.com/trials/santyl-applications-to-diabetic-foot-ulcers-6486https://curecurrent.com/trials/study-of-secukinumab-in-patients-with-newly-diagnosed-type-1-diabetes-mellitus-6487https://curecurrent.com/trials/autologous-dendritic-cell-therapy-for-type-1-diabetes-suppression-a-safety-study-6488https://curecurrent.com/trials/effects-of-stevia-on-satiety-and-eating-attitudes-in-healthy-overweight-and-obese-adults-6489https://curecurrent.com/trials/caloric-restriction-exercise-and-glucoregulation-in-humans-6490https://curecurrent.com/trials/phase-1-study-of-anti-glycation-agent-gly-230-in-healthy-subjects-6491https://curecurrent.com/trials/immunosuppressive-medications-for-participants-in-itn005ct-nct00014911-6492https://curecurrent.com/trials/biod-531-vs-humalog-mix-75-25-vs-humulin-r-u-500-post-meal-glucose-control-in-patients-with-severe-insulin-resistance-6493https://curecurrent.com/trials/comparison-of-postprandial-glucose-control-associated-with-biod-531-vs-humalog-mix-75-25-vs-humulin-r-u-500-6494https://curecurrent.com/trials/impact-of-fluid-milk-on-post-meal-glycemia-and-insulinemia-in-overwt-obese-adults-6495https://curecurrent.com/trials/safety-study-to-lower-the-risk-of-heart-failure-is-also-effective-in-reducing-stiffness-of-the-arteries-6496https://curecurrent.com/trials/a-pilot-study-of-hemin-therapy-for-gastroparesis-diabetes-mellitus-6497https://curecurrent.com/trials/gestational-diabetes-diagnostic-methods-6498https://curecurrent.com/trials/a-feasibility-study-to-assess-critical-aspects-of-fluorescence-affinity-sensor-fas-performance-and-safety-over-several-h-6499https://curecurrent.com/trials/effects-of-pioglitazone-on-platelet-function-6500https://curecurrent.com/trials/effects-of-pulsed-intravenous-iv-insulin-on-brittle-and-uncontrolled-diabetes-6501https://curecurrent.com/trials/a-pilot-study-of-switching-from-one-pain-medication-to-another-opioid-rotation-6502https://curecurrent.com/trials/grafixcore-open-label-study-to-evaluate-the-safety-and-efficacy-of-grafixcore-for-complex-diabetic-foot-wounds-6503https://curecurrent.com/trials/impact-of-decision-aids-to-enhance-shared-decision-making-for-diabetes-6504https://curecurrent.com/trials/endotoxin-and-intestinal-flora-before-and-after-gastric-bypass-or-banding-in-diabetics-6505https://curecurrent.com/trials/md2me-texting-to-promote-chronic-disease-management-6506https://curecurrent.com/trials/genetics-of-peripheral-artery-genomics-6507https://curecurrent.com/trials/advanced-comprehensive-diabetes-care-for-veterans-with-poorly-controlled-diabetes-6508https://curecurrent.com/trials/a-portion-controlled-diet-will-prevent-weight-gain-in-diabetics-treated-with-actos-6509https://curecurrent.com/trials/study-of-how-dulaglutide-compares-to-placebo-in-participants-with-type-2-diabetes-who-are-also-on-sulfonylurea-therapy-a-6510https://curecurrent.com/trials/a-study-to-evaluate-the-effect-of-lipid-infusion-on-toll-like-receptor-4-tlr4-signaling-6511https://curecurrent.com/trials/healthy-transitions-menopause-effect-on-obesity-energy-balance-and-insulin-6512https://curecurrent.com/trials/switching-from-insulin-glargine-to-insulin-degludec-in-subjects-with-type-2-diabetes-mellitus-begin-6513https://curecurrent.com/trials/text-messaging-for-weight-loss-6514https://curecurrent.com/trials/empowering-rural-african-american-women-and-communities-to-improve-diabetes-outcomes-6515https://curecurrent.com/trials/patient-transitioning-from-exubera-inhalation-powder-to-technosphere-insulin-inhalation-powder-6516https://curecurrent.com/trials/comparing-diabetes-prevention-programs-6517https://curecurrent.com/trials/the-effect-of-type-1-diabetes-on-pan-arterial-vascular-function-and-insulin-sensitivity-in-humans-6518https://curecurrent.com/trials/recent-gdm-lifestyle-intervention-6519https://curecurrent.com/trials/synchronization-to-improve-non-adherence-to-cardiovascular-medications-6520https://curecurrent.com/trials/the-medication-metronome-project-study-to-facilitate-follow-up-testing-resulting-from-prescribed-medications-to-improve-6521https://curecurrent.com/trials/effect-of-pioglitazone-on-timp-3-and-tace-in-type-2-diabetes-6522https://curecurrent.com/trials/robust-evaluation-to-measure-improvements-in-nonadherence-from-low-cost-devices-6523https://curecurrent.com/trials/prevention-of-self-care-deterioration-in-early-adolescents-with-diabetes-6524https://curecurrent.com/trials/teens-connect-preventive-psycho-education-for-transitioning-teens-with-diabetes-6525https://curecurrent.com/trials/natural-language-processing-and-quality-assessment-in-primary-care-6526https://curecurrent.com/trials/text-message-reminders-to-increase-rates-of-postpartum-diabetes-screening-in-women-with-gestational-diabetes-6527https://curecurrent.com/trials/a-pilot-study-of-the-provant-therapy-system-in-subjects-with-diabetic-foot-ulcers-6528https://curecurrent.com/trials/mobile-phone-based-intervention-for-promoting-healthy-habits-and-weight-loss-6529https://curecurrent.com/trials/diabetes-lipoproteins-and-accelerated-vascular-disease-6530https://curecurrent.com/trials/the-effect-of-synching-prescription-refills-on-adherence-6531https://curecurrent.com/trials/effect-of-fenugreek-on-blood-sugar-and-insulin-in-diabetic-humans-6532https://curecurrent.com/trials/prediabetes-prehypertension-and-vitamin-d-supplementation-a-practice-based-clinical-intervention-pilot-study-6533https://curecurrent.com/trials/take-time-pioglitazone-reverses-defects-in-mitochondrial-biogenesis-in-patients-with-t2dm-6534https://curecurrent.com/trials/motivational-interviewing-and-cognitive-behavioral-therapy-based-intervention-for-cardiovascular-disease-prevention-amon-6535https://curecurrent.com/trials/inpatient-self-monitoring-and-administration-study-ismas-6536https://curecurrent.com/trials/insulin-resistance-before-and-during-pregnancy-in-women-with-polycystic-ovary-syndrome-6537https://curecurrent.com/trials/regadenoson-blood-flow-in-type-1-diabetes-rabit1d-6538https://curecurrent.com/trials/regulation-of-arginine-vasopressin-avp-6539https://curecurrent.com/trials/take-charge-of-your-diabetes-6540https://curecurrent.com/trials/evaluation-of-curexcell-in-treating-lower-extremity-chronic-ulcers-in-adults-with-diabetes-6541https://curecurrent.com/trials/phase-2b-multicenter-randomized-double-blind-placebo-and-active-controlled-parallel-group-study-to-assess-the-pd-respons-6542https://curecurrent.com/trials/the-ibep-study-an-intervention-for-lifestyle-modification-in-women-with-gestational-diabetes-6543https://curecurrent.com/trials/continuous-glucose-monitoring-cgm-in-subjects-with-type-2-diabetes-taking-twice-daily-exenatide-or-once-weekly-exenatide-6544https://curecurrent.com/trials/clinical-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-pks-of-zydpla1-following-oral-administration-in-6545https://curecurrent.com/trials/impact-of-self-monitoring-blood-glucose-frequency-on-glycemic-control-in-patients-with-type-2-diabetes-6546https://curecurrent.com/trials/establishing-ambulatory-glucose-profiles-for-people-without-diabetes-using-cgm-data-6547https://curecurrent.com/trials/develop-novel-methods-to-display-report-and-analyze-cgm-data-for-clinical-decision-making-in-people-with-diabetes-6548https://curecurrent.com/trials/use-of-continuous-glucose-monitoring-combined-with-ambulatory-glucose-profiles-to-characterize-glycemic-control-6549https://curecurrent.com/trials/training-doctors-to-support-patient-self-care-of-depression-6550https://curecurrent.com/trials/characteristics-of-persons-with-an-eating-disorder-and-type-1-diabetes-6551https://curecurrent.com/trials/the-impact-of-food-on-blood-sugar-in-people-with-type-2-diabetes-6552https://curecurrent.com/trials/impact-of-periodontal-disease-on-outcomes-in-diabetes-6553https://curecurrent.com/trials/support-group-surveys-for-individuals-who-have-type-1-diabetes-and-an-eating-disorder-6554https://curecurrent.com/trials/using-continuous-glucose-monitoring-to-understand-the-glycemic-impact-of-food-6555https://curecurrent.com/trials/the-empathy-toolkit-helping-diabetes-patients-overcome-barriers-to-medication-adherence-6556https://curecurrent.com/trials/impact-of-continuing-medical-education-cme-insulin-program-6557https://curecurrent.com/trials/glycemic-effect-of-colesevelam-hcl-welchol-in-patients-with-type-2-diabetes-6558https://curecurrent.com/trials/observational-study-of-interstitial-glucose-monitoring-with-continuous-glucose-monitoring-to-track-patients-treated-with-6559https://curecurrent.com/trials/type-1-diabetes-and-eating-disorder-diurnal-glucose-patterns-6560https://curecurrent.com/trials/evaluation-of-glucose-monitoring-methods-characterizing-glycemic-control-in-subjects-with-diabetes-6561https://curecurrent.com/trials/continuous-glucose-monitoring-self-monitored-blood-glucose-type-2-therapy-matrix-definition-6562https://curecurrent.com/trials/assessment-of-non-fasting-vs-fasting-lipid-measures-in-diabetes-patients-6563https://curecurrent.com/trials/modal-day-analysis-of-self-monitoring-blood-glucose-versus-continuous-glucose-monitoring-6564https://curecurrent.com/trials/barriers-to-the-implementation-of-complete-insulin-order-sets-6565https://curecurrent.com/trials/the-use-of-a-computer-program-to-help-primary-care-providers-treat-patients-with-type-2-diabetes-6566https://curecurrent.com/trials/fat-induced-insulin-resistance-and-atherosclerosis-6567https://curecurrent.com/trials/glycemic-response-to-oral-nutrition-supplements-6568https://curecurrent.com/trials/medication-adherence-with-polyglot-meducation-6569https://curecurrent.com/trials/a-pilot-study-of-metabolic-effects-of-omentectomy-6570https://curecurrent.com/trials/estimation-of-malignancy-rates-within-humedica-patient-populations-sampled-to-be-representative-of-liraglutide-initiator-6571https://curecurrent.com/trials/pilot-study-cardiovascular-events-in-high-risk-orthopedic-surgical-patients-6572https://curecurrent.com/trials/effects-of-qigong-on-type-2-diabetic-patients-6573https://curecurrent.com/trials/quantitative-18f-av-133-pet-imaging-in-subjects-with-diabetes-and-healthy-controls-6574https://curecurrent.com/trials/multiple-ascending-dose-study-in-subjects-with-type-2-diabetes-6575https://curecurrent.com/trials/a-comparative-efficacy-study-of-dermapure-to-treat-diabetic-foot-ulcers-6576https://curecurrent.com/trials/risk-factors-for-implant-bone-loss-in-patients-with-diabetes-mellitus-6577https://curecurrent.com/trials/pharmacogenetics-of-ace-inhibitor-associated-angioedema-6578https://curecurrent.com/trials/diabetes-technology-study-of-real-time-glucose-alerts-in-the-team-management-of-diabetes-6579https://curecurrent.com/trials/translating-a-heart-disease-lifestyle-intervention-into-the-community-6580https://curecurrent.com/trials/retinal-blood-flow-and-microthrombi-in-type-1-diabetes-6581https://curecurrent.com/trials/safety-and-efficacy-study-of-pyridorin-in-patients-with-nephropathy-due-to-type-2-diabetes-6582https://curecurrent.com/trials/prevalence-of-inpatient-hyperglycemia-risks-complications-and-outcomes-6583https://curecurrent.com/trials/increasing-medication-adherence-through-physician-incentives-and-messaging-6584https://curecurrent.com/trials/continuous-glucose-monitoring-to-measure-effect-of-glycemic-index-6585https://curecurrent.com/trials/moderate-to-vigorous-physical-activity-for-glycemic-control-in-patients-with-gestational-diabetes-mellitus-6586https://curecurrent.com/trials/crossover-feasibility-study-of-portable-ap-device-with-zone-mpc-and-hms-and-adapted-i-c-and-basal-insulin-6587https://curecurrent.com/trials/a-phase-2-multi-center-study-to-evaluate-the-efficacy-and-safety-of-a-chemokine-ccr2-5-receptor-antagonist-in-adults-wit-6588https://curecurrent.com/trials/a-phase-iii-study-of-bms-512148-dapagliflozin-in-patients-with-type-2-diabetes-who-are-not-well-controlled-with-diet-and-6589https://curecurrent.com/trials/a-phase-iii-study-of-bms-512148-dapagliflozin-in-patients-with-type-2-diabetes-who-are-not-well-controlled-on-metformin-6590https://curecurrent.com/trials/evidence-based-amputee-rehabilitation-ebar-program-6591https://curecurrent.com/trials/practice-based-nutrition-intervention-2-6592https://curecurrent.com/trials/comparison-of-two-pharmacist-led-population-management-approaches-to-increase-monitoring-of-vitamin-b12-and-serum-creati-6593https://curecurrent.com/trials/study-of-tak-875-in-adults-with-type-2-diabetes-and-cardiovascular-disease-or-risk-factors-for-cardiovascular-disease-6594https://curecurrent.com/trials/regulation-of-branched-chain-amino-acid-metabolism-in-pre-diabetes-6595https://curecurrent.com/trials/breakfast-nutrition-and-inpatient-glycemia-6596https://curecurrent.com/trials/trial-of-an-herb-and-mineral-combination-product-on-fasting-glucose-in-adults-at-risk-for-developing-diabetes-6597https://curecurrent.com/trials/examining-the-effects-of-diet-on-health-with-an-online-program-6598https://curecurrent.com/trials/effect-of-discontinuation-of-sugar-sweetened-beverages-6599https://curecurrent.com/trials/safety-study-of-bms-823778-in-subjects-with-type-2-diabetes-6600https://curecurrent.com/trials/safety-study-of-bms-770767-in-subjects-with-type-2-diabetes-6601https://curecurrent.com/trials/mobile-insulin-titration-intervention-6602https://curecurrent.com/trials/diabetes-prevention-program-pilot-study-6603https://curecurrent.com/trials/a-pilot-study-to-determine-the-safety-of-campath-1h-anti-cd52-antibody-therapy-in-newly-diagnosed-subjects-with-type-1-d-6604https://curecurrent.com/trials/a-brief-intervention-to-improve-medication-knowledge-and-adherence-among-family-medicine-patients-in-south-texas-6605https://curecurrent.com/trials/interprofessional-training-to-improve-diabetes-care-the-respect-trial-6606https://curecurrent.com/trials/oral-and-non-insulin-injected-hypoglycemic-therapy-utilization-patterns-6607https://curecurrent.com/trials/teamcare-for-diabetes-in-mental-health-centers-6608https://curecurrent.com/trials/effectiveness-and-safety-study-of-the-dexcom-g4-continuous-glucose-monitoring-system-6609https://curecurrent.com/trials/gastric-sleeve-pilot-study-in-morbidly-obese-undergoing-liver-transplantation-6610https://curecurrent.com/trials/improving-prevention-of-heart-disease-in-latinos-6611https://curecurrent.com/trials/free-test-strips-and-blood-glucose-control-6612https://curecurrent.com/trials/evaluation-of-programs-of-coordinated-care-and-disease-management-6613https://curecurrent.com/trials/laser-therapy-for-diabetic-peripheral-neuropathic-pain-6614https://curecurrent.com/trials/comparison-of-fasiglifam-tak-875-with-sitagliptin-when-used-in-combination-with-metformin-in-patients-with-type-2-diabet-6615https://curecurrent.com/trials/comparison-of-two-nn1250-formulations-in-healthy-volunteers-6616https://curecurrent.com/trials/a-comparison-between-two-formulations-of-nn5401-in-healthy-subjects-6617https://curecurrent.com/trials/effect-of-a-high-protein-diet-and-or-high-intensity-training-on-metabolic-syndrome-6618https://curecurrent.com/trials/improving-diabetes-outcomes-through-lifestyle-change-idolc-study-6619https://curecurrent.com/trials/blood-flow-responses-to-an-oral-glucose-tolerance-test-in-type-2-diabetes-6620https://curecurrent.com/trials/an-observational-study-to-assess-longitudinal-variation-of-immune-biomarkers-in-subjects-at-risk-for-development-of-type-6621https://curecurrent.com/trials/evaluation-of-the-bioavailability-of-pramlintide-6622https://curecurrent.com/trials/evaluation-of-dose-titration-of-pramlintide-during-initiation-of-therapy-in-patients-trying-to-improve-glucose-control-6623https://curecurrent.com/trials/using-patient-feedback-to-improve-communication-regarding-glycemic-control-to-patients-with-diabetes-6624https://curecurrent.com/trials/study-of-the-long-term-safety-of-pramlintide-in-subjects-with-type-1-diabetes-mellitus-6625https://curecurrent.com/trials/study-of-human-regular-u-500-insulin-in-adult-participants-with-type-2-diabetes-6626https://curecurrent.com/trials/a-study-to-examine-the-pharmacokinetics-tolerability-safety-and-efficacy-of-exenatide-once-weekly-suspension-6627https://curecurrent.com/trials/controlling-disease-using-inexpensive-it-hypertension-in-diabetes-6628https://curecurrent.com/trials/mechanisms-of-diabetes-control-after-weight-loss-surgery-sub-study-1-6629https://curecurrent.com/trials/very-low-calorie-diet-for-diabetic-kidney-disease-6630https://curecurrent.com/trials/effectiveness-of-manual-manipulation-with-epat-on-ankle-dorsiflexion-and-dynamic-plantar-pressure-6631https://curecurrent.com/trials/effects-of-exenatide-long-acting-release-on-glucose-control-and-safety-in-subjects-with-type-2-diabetes-mellitus-duratio-6632https://curecurrent.com/trials/a-study-to-compare-the-effects-of-exenatide-and-sitagliptin-on-postprandial-glucose-in-subjects-with-type-2-diabetes-mel-6633https://curecurrent.com/trials/challenging-the-gold-standard-pilot-study-comparing-continuous-glucose-monitoring-system-cgms-capillary-glucose-monitors-6634https://curecurrent.com/trials/pilot-study-of-exenatide-pharmacokinetics-and-pharmacodynamics-in-gestational-diabetes-6635https://curecurrent.com/trials/veterans-walk-for-health-study-6636https://curecurrent.com/trials/a-study-to-examine-the-efficacy-safety-and-tolerability-and-pharmacokinetics-of-exenatide-once-monthly-suspension-6637https://curecurrent.com/trials/comparison-study-of-the-glycemic-effects-safety-and-tolerability-of-exenatide-once-weekly-suspension-to-sitagliptin-and-6638https://curecurrent.com/trials/study-on-the-impact-of-patient-navigators-on-the-health-education-and-quality-of-life-in-formerly-incarcerated-patients-6639https://curecurrent.com/trials/a-study-to-evaluate-itca-650-for-the-treatment-of-type-2-diabetes-6640https://curecurrent.com/trials/comparative-study-of-amniotic-membrane-wound-graft-in-the-management-of-diabetic-foot-ulcers-6641https://curecurrent.com/trials/improved-glycemic-control-in-adult-subjects-with-type-1-diabetes-on-mdi-using-insulin-guidance-software-6642https://curecurrent.com/trials/a-transgenerational-e-intervention-for-gestational-diabetics-and-their-offspring-6643https://curecurrent.com/trials/postpartum-diabetes-screening-in-women-with-gestational-diabetes-6644https://curecurrent.com/trials/effect-of-testosterone-gel-replacement-on-fat-mass-in-males-with-low-testosterone-levels-and-diabetes-6645https://curecurrent.com/trials/validation-of-a-patient-decision-aid-for-type-2-diabetes-6646https://curecurrent.com/trials/length-of-effect-of-extended-release-aspirin-on-platelets-in-patients-with-diabetes-and-heart-disease-6647https://curecurrent.com/trials/e-pharmacovigilance-ii-surveillance-for-safety-and-effectiveness-calling-for-earlier-detection-of-adverse-reactions-6648https://curecurrent.com/trials/to-evaluate-the-effect-on-post-prandial-glycemia-safety-and-tolerability-of-viaject-7-vs-lispro-insulin-during-subcutane-6649https://curecurrent.com/trials/a-clinical-study-of-the-performance-of-a-glucose-blinding-protein-based-continuous-glucose-monitor-gbp-cgm-6650https://curecurrent.com/trials/antioxidant-effects-of-pomegranate-juice-versus-placebo-in-adults-with-type-2-diabetes-mellitus-6651https://curecurrent.com/trials/dka-optic-ultrasound-6652https://curecurrent.com/trials/dietary-interventions-in-prediabetes-6653https://curecurrent.com/trials/a-study-comparing-the-pharmacodynamic-properties-of-insulin-viaject-regular-human-insulin-and-insulin-lispro-6654https://curecurrent.com/trials/depression-diabetes-mechanisms-urban-african-americans-6655https://curecurrent.com/trials/a-study-evaluating-safety-and-efficacy-of-biod-123-compared-to-insulin-lispro-humalog-6656https://curecurrent.com/trials/ffa-hypertension-and-inflammation-in-lean-and-obese-subjects-6657https://curecurrent.com/trials/diabetic-kidney-disease-influence-of-exercise-therapy-on-physical-and-vascular-function-6658https://curecurrent.com/trials/the-i-kan-study-internet-insulin-education-for-kansans-6659https://curecurrent.com/trials/training-effects-on-skeletal-muscle-fatty-acid-metabolism-6660https://curecurrent.com/trials/a-16-weeks-study-on-efficacy-and-safety-of-two-doses-of-empagliflozin-bi-10773-once-daily-versus-twice-daily-in-patients-6661https://curecurrent.com/trials/mobile-motivation-for-health-promotion-among-adolescents-6662https://curecurrent.com/trials/effect-of-raised-cbf-during-cea-on-cognition-in-dm-patients-6663https://curecurrent.com/trials/recombinant-human-leptin-therapy-effects-on-insulin-action-6664https://curecurrent.com/trials/accuracy-study-for-enhanced-meter-feature-6665https://curecurrent.com/trials/a-phase-2-study-of-the-safety-and-efficacy-of-thymosin-beta-4-for-treating-corneal-wounds-6666https://curecurrent.com/trials/effects-of-hyperglycemia-on-myocardial-perfusion-in-humans-with-and-without-type-2-diabetes-6667https://curecurrent.com/trials/intervention-to-increase-screening-for-glucocorticoid-induced-diabetes-6668https://curecurrent.com/trials/safety-effectiveness-on-vascular-structure-and-function-of-acz885-in-atherosclerosis-and-either-t2dm-or-igt-patients-6669https://curecurrent.com/trials/effect-of-lycopene-and-isoflavones-on-glucose-metabolism-6670https://curecurrent.com/trials/effects-of-treating-vitamin-d-deficiency-in-poorly-controlled-type-2-diabetes-6671https://curecurrent.com/trials/nerve-decompression-for-ulcer-recurrence-avoidance-dura-6672https://curecurrent.com/trials/comparison-of-a-new-formulation-of-insulin-glargine-with-lantus-in-patients-with-type-1-diabetes-mellitus-6673https://curecurrent.com/trials/comparison-of-a-new-formulation-of-insulin-glargine-with-lantus-in-patients-with-type-2-diabetes-on-non-insulin-antidiab-6674https://curecurrent.com/trials/pramlintide-in-adolescents-with-type-1-diabetes-6675https://curecurrent.com/trials/improving-outcomes-in-diabetic-patients-during-cabg-surgery-by-optimizing-glycemic-control-6676https://curecurrent.com/trials/study-of-saxagliptin-5-hydroxy-saxagliptin-and-metformin-concentrations-levels-in-pediatric-subjects-with-t2dm-6677https://curecurrent.com/trials/ketosis-prone-diabetes-mellitus-kpdm-metformin-versus-sitagliptin-treatment-6678https://curecurrent.com/trials/cognitive-behavioral-therapy-for-diabetic-neuropathic-pain-6679https://curecurrent.com/trials/diabetes-telemedicine-consultation-a-systems-improvement-intervention-6680https://curecurrent.com/trials/efficacy-of-exenatide-once-weekly-and-once-daily-insulin-glargine-in-patients-with-type-2-diabetes-treated-with-metformi-6681https://curecurrent.com/trials/a-surgical-approach-to-the-management-of-type-ii-diabetes-mellitus-in-patients-with-a-bmi-between-25-35-kg-m2-6682https://curecurrent.com/trials/a-phase-2-multicenter-randomized-double-blind-placebo-controlled-study-for-the-pain-of-diabetic-peripheral-neuropathy-6683https://curecurrent.com/trials/safety-and-tolerability-study-of-oral-lgd-6972-for-type-2-diabetes-mellitus-6684https://curecurrent.com/trials/sympathetic-nerve-activity-during-hypoglycemia-and-exercise-6685https://curecurrent.com/trials/ezcast-dfu-study-with-portal-for-application-of-topical-medications-6686https://curecurrent.com/trials/mechanisms-of-hypoglycemia-associated-autonomic-dysfunction-q-3-6687https://curecurrent.com/trials/role-of-macronutrient-diet-composition-and-infant-metabolic-outcomes-in-gestational-diabetes-6688https://curecurrent.com/trials/self-management-and-resourceful-transition-of-type-2-diabetes-with-stage-3-kidney-disease-6689https://curecurrent.com/trials/managing-diabetes-in-pregnancy-using-cell-phone-internet-technology-6690https://curecurrent.com/trials/intensive-case-diabetes-management-icdm-to-prevent-readmission-6691https://curecurrent.com/trials/effects-of-dark-chocolate-on-exercise-capacity-and-mitochondrial-structure-and-function-6692https://curecurrent.com/trials/partners-in-care-with-semi-structured-support-group-6693https://curecurrent.com/trials/cardiometabolic-program-meets-ehealth-redesign-and-evaluation-for-optimal-reach-and-impact-6694https://curecurrent.com/trials/effectiveness-of-v-go-for-patients-with-diabetes-in-a-real-world-setting-6695https://curecurrent.com/trials/comparison-of-a-new-formulation-of-insulin-glargine-with-lantus-in-patients-with-type-1-diabetes-mellitus-on-basal-plus-6696https://curecurrent.com/trials/mood-and-diabetes-empowerment-improvement-training-6697https://curecurrent.com/trials/safety-and-efficacy-of-saxagliptin-plus-insulin-with-or-without-metformin-6698https://curecurrent.com/trials/bioequivalence-study-of-saxagliptin-and-glucophage-combination-formulations-in-healthy-subjects-a-6699https://curecurrent.com/trials/efficacy-and-safety-study-of-saxagliptin-metformin-immediate-release-ir-versus-metformin-ir-alone-in-type-2-diabetes-mel-6700https://curecurrent.com/trials/safety-and-efficacy-study-of-subjects-that-are-taking-saxagliptin-added-onto-metformin-xr-compared-to-subjects-taking-me-6701https://curecurrent.com/trials/mechanistic-assessment-of-the-properties-of-saxagliptin-in-subjects-undergoing-coronary-artery-bypass-graft-surgery-6702https://curecurrent.com/trials/va-nephron-d-diabetes-in-nephropathy-study-6703https://curecurrent.com/trials/treat-telemedicine-for-reach-education-access-and-treatment-6704https://curecurrent.com/trials/pogo-automatic-blood-glucose-monitoring-system-clinical-study-6705https://curecurrent.com/trials/neuropeptides-and-social-behavior-6706https://curecurrent.com/trials/study-on-the-role-of-decompression-of-lower-extremity-nerves-for-the-treatment-of-patients-with-symptomatic-diabetic-neu-6707https://curecurrent.com/trials/safety-and-tolerability-of-nova63035-corticosteroid-in-patients-with-diabetic-macular-edema-secondary-to-diabetic-retino-6708https://curecurrent.com/trials/effective-treatment-of-sleep-apnea-in-prediabetes-to-reduce-cardiometabolic-risk-6709https://curecurrent.com/trials/understanding-and-improving-diabetes-care-for-ethnic-minorities-6710https://curecurrent.com/trials/local-modulation-of-immune-receptors-to-enhance-the-response-to-dendritic-cell-vaccination-in-metastatic-melanoma-6711https://curecurrent.com/trials/project-diabetes-prescription-for-healthy-living-6712https://curecurrent.com/trials/linking-self-management-and-primary-care-for-diabetes-2-6713https://curecurrent.com/trials/diabetes-support-project-couples-intervention-6714https://curecurrent.com/trials/bioequivalence-study-of-the-fixed-dose-combination-of-5-mg-saxagliptin-and-500-mg-metformin-xr-tablet-manufactured-in-mt-6715https://curecurrent.com/trials/evaluation-of-an-orally-administered-medication-when-taken-in-conjunction-with-pramlintide-6716https://curecurrent.com/trials/study-of-duodenal-jejunal-bypass-djb-as-a-potential-cure-for-type-2-diabetes-mellitus-6717https://curecurrent.com/trials/clinical-utility-and-safety-of-pramlintide-in-subjects-with-type-1-and-type-2-diabetes-mellitus-6718https://curecurrent.com/trials/bioequivalence-study-of-saxagliptin-and-glucophage-combination-formulations-in-healthy-subjects-b-6719https://curecurrent.com/trials/study-of-impact-of-behavioral-intervention-exercise-nutrition-education-on-body-mass-index-bmi-6720https://curecurrent.com/trials/study-to-evaluate-24-hour-blood-sugar-control-24-hour-mean-weighted-glucose-in-subjects-that-are-taking-saxagliptin-5-mg-6721https://curecurrent.com/trials/minocycline-and-proteinuria-in-diabetic-nephropathy-6722https://curecurrent.com/trials/a-phase-2b-study-of-gcs-100-in-patients-with-chronic-kidney-disease-caused-by-diabetes-6723https://curecurrent.com/trials/impaired-family-dynamics-leads-to-non-compliance-in-type-i-diabetes-6724https://curecurrent.com/trials/insulin-resistance-in-type-i-diabetes-in-pediatric-care-6725https://curecurrent.com/trials/artificial-pancreas-control-system-in-an-outpatient-setting-6726https://curecurrent.com/trials/safety-and-efficacy-of-gentamicin-topical-gel-appligel-g-for-treatment-of-mild-to-moderately-infected-diabetic-foot-ulce-6727https://curecurrent.com/trials/oral-thiamine-for-the-treatment-of-painful-diabetic-peripheral-neuropathy-6728https://curecurrent.com/trials/utility-of-crocsrx-clog-as-a-diabetic-house-shoe-a-pilot-study-6729https://curecurrent.com/trials/cardiovascular-disease-education-and-problem-solving-training-in-people-with-type-2-diabetes-6730https://curecurrent.com/trials/bioequivalence-study-of-2-5-mg-saxagliptin-and-500-mg-glucophage-in-tablets-and-a-fixed-dose-combination-tablet-in-healt-6731https://curecurrent.com/trials/bioequivalence-study-of-the-fixed-dose-combination-of-5-mg-saxagliptin-1000-mg-metformin-xr-manufactured-in-mt-vernon-in-6732https://curecurrent.com/trials/effect-of-a-low-advanced-glycation-end-products-age-diet-in-the-metabolic-syndrome-6733https://curecurrent.com/trials/do-group-insulin-education-visits-reduce-barriers-to-insulin-initiation-6734https://curecurrent.com/trials/drug-interaction-study-of-saxagliptin-in-combination-with-dapagliflozin-in-healthy-participants-6735https://curecurrent.com/trials/bioequivalence-study-of-fixed-dose-combination-of-2-5-mg-saxagliptin-850-mg-metformin-tablet-relative-to-2-5-mg-onglyza-6736https://curecurrent.com/trials/project-wellness-increasing-hiv-testing-among-west-african-immigrants-6737https://curecurrent.com/trials/bioequivalence-study-of-500-mg-and-1000-mg-glucophage-metformin-tablets-in-healthy-subjects-6738https://curecurrent.com/trials/multi-arm-intervention-diabetes-adherence-study-6739https://curecurrent.com/trials/metformin-to-treat-obesity-in-children-with-insulin-resistance-6740https://curecurrent.com/trials/feasibility-study-to-evaluate-safety-and-device-performance-of-the-hospital-glucose-management-system-hgms-6741https://curecurrent.com/trials/a-study-assessing-saxagliptin-treatment-in-subjects-with-type-2-diabetes-who-are-not-controlled-with-diet-and-exercise-6742https://curecurrent.com/trials/efficacy-and-safety-of-azilsartan-medoxomil-used-in-combination-with-metformin-in-participants-with-hypertension-and-dia-6743https://curecurrent.com/trials/pharmacokinetics-and-pharmacodynamics-study-of-saxagliptin-in-healthy-subjects-6744https://curecurrent.com/trials/lifestyle-modification-for-type-2-diabetes-involving-reduction-of-after-meal-blood-glucose-elevations-6745https://curecurrent.com/trials/a-study-of-saxagliptin-in-subjects-with-type-2-diabetes-who-have-inadequate-blood-sugar-control-with-sulfonylureas-6746https://curecurrent.com/trials/safety-study-of-repeated-doses-of-glucagon-on-animal-starch-in-the-liver-6747https://curecurrent.com/trials/safety-and-efficacy-study-of-metaglidasen-in-type-2-diabetes-in-patients-suboptimally-controlled-on-insulin-6748https://curecurrent.com/trials/safety-and-tolerability-study-of-mbx-2044-in-patients-with-type-2-diabetes-6749https://curecurrent.com/trials/study-of-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-single-oral-doses-of-jtt-252-6750https://curecurrent.com/trials/detection-of-human-beta-cell-death-in-type-1-diabetes-mellitus-t1dm-by-methylation-specific-polymerase-chain-reaction-pc-6751https://curecurrent.com/trials/using-eeg-operant-conditioning-to-improve-trait-self-control-and-promote-healthy-behavior-6752https://curecurrent.com/trials/regional-fatty-acid-metabolism-in-humans-6753https://curecurrent.com/trials/study-assessing-saxagliptin-treatment-in-type-2-diabetic-subjects-who-are-not-controlled-with-metformin-alone-6754https://curecurrent.com/trials/a-phase-3-study-of-bms-477118-in-combination-with-metformin-in-subjects-with-type-2-diabetes-who-are-not-controlled-with-6755https://curecurrent.com/trials/study-of-bms-477118-as-monotherapy-with-titration-in-subjects-with-type-2-diabetes-who-are-not-controlled-with-diet-and-6756https://curecurrent.com/trials/study-to-evaluate-the-safety-tolerability-and-efficacy-of-three-dose-levels-of-mitoglitazone-in-type-2-diabetic-patients-6757https://curecurrent.com/trials/veterans-service-organizations-and-my-healthevet-mhv-6758https://curecurrent.com/trials/effective-care-management-of-depressed-diabetes-patients-the-positive-steps-study-6759https://curecurrent.com/trials/use-of-online-personalized-health-record-system-to-promote-self-management-of-diabetes-6760https://curecurrent.com/trials/adherence-and-intensification-of-medications-aim-implementation-study-6761https://curecurrent.com/trials/racial-ethnic-differences-in-trust-mistrust-and-its-effect-on-diabetes-outcomes-6762https://curecurrent.com/trials/nurse-telephone-management-of-cholesterol-in-diabetes-6763https://curecurrent.com/trials/diabetes-medication-choice-6764https://curecurrent.com/trials/opportunistic-screening-for-prediabetes-and-early-diabetes-in-primary-care-6765https://curecurrent.com/trials/a-nutritional-intervention-for-diabetic-neuropathy-wccr-dn2-6766https://curecurrent.com/trials/enhancing-fitness-in-older-pre-diabetic-veterans-6767https://curecurrent.com/trials/diabetes-assistant-dias-control-to-range-ctr-nocturnal-closed-loop-camp-study-6768https://curecurrent.com/trials/genetic-testing-for-type-2-diabetes-6769https://curecurrent.com/trials/pilot-study-to-determine-effects-of-salsalate-in-type-1-diabetes-and-painful-peripheral-neuropathy-6770https://curecurrent.com/trials/improving-insulin-therapy-with-enhanced-care-management-6771https://curecurrent.com/trials/family-supported-smoking-cessation-for-chronically-ill-veterans-6772https://curecurrent.com/trials/effect-of-vitamin-d-supplementation-on-hemoglobin-a1c-6773https://curecurrent.com/trials/bioequivalence-study-6774https://curecurrent.com/trials/effect-of-physical-activity-on-metabolic-syndrome-in-pregnancy-fetal-outcome-6775https://curecurrent.com/trials/a-placebo-controlled-randomized-safety-and-efficacy-study-to-evaluate-the-change-in-hemoglobin-a1c-levels-in-type-2-diab-6776https://curecurrent.com/trials/metabolic-surgery-versus-medical-management-for-resolution-of-type-ii-diabetes-6777https://curecurrent.com/trials/computed-tomography-and-biomarker-analysis-in-diagnosing-coronary-artery-disease-in-asymptomatic-patients-who-have-under-6778https://curecurrent.com/trials/safety-of-exenatide-once-weekly-in-patients-with-type-2-diabetes-mellitus-treated-with-thiazolidinedione-alone-or-thiazo-6779https://curecurrent.com/trials/a-study-of-ly2189265-compared-to-sitagliptin-in-participants-with-type-2-diabetes-mellitus-on-metformin-6780https://curecurrent.com/trials/study-of-denagliptin-in-subjects-with-type-2-diabetes-mellitus-t2dm-6781https://curecurrent.com/trials/safety-pharmacokinetics-pk-and-pharmacodynamics-pd-of-multiple-oral-bedtime-doses-of-ormd-0801-in-adult-patients-with-ty-6782https://curecurrent.com/trials/pilot-study-of-vedic-medicine-for-type-2-diabetes-6783https://curecurrent.com/trials/gsk189075-gw869682-or-placebo-in-type-2-diabetic-patients-6784https://curecurrent.com/trials/a-retrospective-cohort-study-of-acute-pancreatitis-in-relation-to-use-of-exenatide-and-other-antidiabetic-agents-6785https://curecurrent.com/trials/glycemic-control-of-carvedilol-versus-metoprolol-in-patients-with-type-ii-diabetes-mellitus-and-hypertension-6786https://curecurrent.com/trials/effect-of-carvedilol-versus-metoprolol-on-glycemic-control-in-patients-with-type-ii-diabetes-and-hypertension-6787https://curecurrent.com/trials/a-study-to-characterize-regimens-of-basal-insulin-intensified-with-either-symlin-or-rapid-acting-insulin-in-patients-wit-6788https://curecurrent.com/trials/a-safety-study-to-assess-the-effects-of-therapeutic-and-supratherapeutic-exenatide-concentrations-on-qt-interval-in-heal-6789https://curecurrent.com/trials/study-of-itca-650-exenatide-in-duros-in-subjects-with-type-2-diabetes-mellitus-6790https://curecurrent.com/trials/effect-of-exenatide-on-abdominal-fat-distribution-in-patients-with-type-2-diabetes-pretreated-with-metformin-6791https://curecurrent.com/trials/safety-and-efficacy-of-exenatide-once-weekly-injection-versus-metformin-dipeptidyl-peptidase-4-inhibitor-or-thiazolidine-6792https://curecurrent.com/trials/comparison-of-the-effect-of-exenatide-versus-sitagliptin-on-24-hour-average-glucose-in-patients-with-type-2-diabetes-on-6793https://curecurrent.com/trials/neulasta-in-type-1-diabetes-6794https://curecurrent.com/trials/effect-of-exercise-on-gait-and-balance-in-peripheral-neuropathy-6795https://curecurrent.com/trials/a-study-assessing-saxagliptin-treatment-in-type-2-diabetic-subjects-who-are-not-controlled-with-tzd-therapy-alone-6796https://curecurrent.com/trials/an-evaluation-of-exenatide-and-rosiglitazone-in-subjects-with-type-2-diabetes-mellitus-6797https://curecurrent.com/trials/automated-calls-with-nurse-follow-up-to-improve-diabetes-ambulatory-care-6798https://curecurrent.com/trials/study-to-evaluate-the-effectiveness-of-a-program-developed-to-improve-eye-care-for-veterans-with-diabetes-6799https://curecurrent.com/trials/safety-and-efficacy-of-exenatide-in-patients-with-type-2-diabetes-using-a-thiazolidinedione-or-a-thiazolidinedione-and-m-6800https://curecurrent.com/trials/improving-diabetes-care-via-telephone-assessment-and-patient-education-6801https://curecurrent.com/trials/improving-health-outcomes-of-diabetic-veterans-a-diabetic-self-management-program-6802https://curecurrent.com/trials/proactive-diabetes-case-management-6803https://curecurrent.com/trials/computer-assisted-access-to-specialist-expertise-6804https://curecurrent.com/trials/effect-of-ac2993-compared-with-insulin-glargine-in-patients-with-type-2-diabetes-also-using-combination-therapy-with-sul-6805https://curecurrent.com/trials/effectiveness-of-home-based-health-messaging-for-patients-with-hypertension-and-diabetes-6806https://curecurrent.com/trials/an-evaluation-of-home-based-telemedicine-services-6807https://curecurrent.com/trials/effect-on-weight-loss-of-exenatide-versus-placebo-6808https://curecurrent.com/trials/type-2-diabetes-self-management-intervention-for-low-income-women-6809https://curecurrent.com/trials/disease-management-and-educational-intervention-outcomes-in-high-risk-diabetics-6810https://curecurrent.com/trials/a-pilot-study-of-effects-of-exenatide-on-body-weight-in-non-diabetic-obese-patients-6811https://curecurrent.com/trials/improving-service-delivery-through-access-points-6812https://curecurrent.com/trials/dermal-thermometry-and-self-care-of-high-risk-diabetic-patients-6813https://curecurrent.com/trials/efficacy-and-safety-study-of-dermal-living-skin-replacement-to-treat-diabetic-foot-ulcers-6814https://curecurrent.com/trials/a-study-to-evaluate-the-glycemic-effects-safety-and-tolerability-of-exenatide-once-weekly-in-subjects-with-type-2-diabet-6815https://curecurrent.com/trials/a-study-to-compare-the-glycemic-effects-safety-and-tolerability-of-exenatide-once-weekly-to-those-of-sitagliptin-and-pio-6816https://curecurrent.com/trials/periodontal-care-and-glycemic-control-in-diabetes-6817https://curecurrent.com/trials/internet-based-diabetes-education-and-case-management-6818https://curecurrent.com/trials/exercise-training-and-glucose-metabolism-in-aging-6819https://curecurrent.com/trials/acute-cardiovascular-and-metabolic-effects-of-exercise-training-in-individuals-with-insulin-resistance-6820https://curecurrent.com/trials/culturally-relevant-exercise-for-diabetes-cure-d-6821https://curecurrent.com/trials/saxagliptin-treatment-in-subjects-with-type-2-diabetes-who-are-not-controlled-with-diet-and-exercise-6822https://curecurrent.com/trials/a-study-to-evaluate-a-multiple-model-probabilistic-predictive-controller-mmppc-for-closed-loop-insulin-delivery-6823https://curecurrent.com/trials/efficacy-and-safety-of-empagliflozin-bi-10773-linagliptin-bi-1356-fixed-dose-combination-in-treatment-na-ve-and-metformi-6824https://curecurrent.com/trials/a-mixed-methods-approach-to-the-development-and-testing-of-the-measure-of-drug-self-management-meds-6825https://curecurrent.com/trials/effects-of-colesevelam-hcl-on-bile-acid-kinetics-6826https://curecurrent.com/trials/cocoa-polyphenols-and-the-kidney-in-healthy-subjects-and-in-subjects-with-hypertension-and-diabetes-mellitus-6827https://curecurrent.com/trials/a-study-evaluating-the-efficacy-and-safety-of-adding-symlin-to-lantus-insulin-glargine-in-subjects-with-type-2-diabetes-6828https://curecurrent.com/trials/milk-as-treatment-for-hypoglycemia-6829https://curecurrent.com/trials/an-observational-study-evaluating-symlin-pramlintide-acetate-injection-use-in-insulin-using-patients-with-type-2-and-typ-6830https://curecurrent.com/trials/a-pilot-open-label-clinical-trial-to-evaluate-the-combined-impact-of-two-mobile-health-products-on-health-outcomes-in-ov-6831https://curecurrent.com/trials/gene-x-behavior-interaction-in-the-look-ahead-study-6832https://curecurrent.com/trials/effects-of-quercetin-on-blood-sugar-and-blood-vessel-function-in-type-2-diabetes-6833https://curecurrent.com/trials/single-site-single-subject-treatment-ind-with-mannkind-corporation-s-technosphere-inhalation-system-6834https://curecurrent.com/trials/pilot-study-of-clinician-supported-patient-self-management-of-hospital-insulin-therapy-6835https://curecurrent.com/trials/preventkd-prevent-risks-by-early-intervention-at-nighttime-in-type-1-diabetes-for-kidney-disease-6836https://curecurrent.com/trials/repaglinide-for-adolescents-with-cystic-fibrosis-related-diabetes-6837https://curecurrent.com/trials/effect-of-ac2993-with-or-without-immunosuppression-on-beta-cell-function-in-patients-with-type-i-diabetes-6838https://curecurrent.com/trials/intensive-lifestyle-intervention-for-type-2-diabetics-the-kp-tlc-pilot-6839https://curecurrent.com/trials/comparing-the-ultrasound-appearance-of-the-sciatic-nerve-with-its-appearance-under-a-microscope-6840https://curecurrent.com/trials/pets-d-parent-education-thru-simulation-diabetes-6841https://curecurrent.com/trials/promoting-physical-activity-among-patients-with-type-2-diabetes-6842https://curecurrent.com/trials/ehealth-second-life-impacts-diabetes-education-self-management-6843https://curecurrent.com/trials/d-vitamin-intervention-in-va-6844https://curecurrent.com/trials/a-study-to-evaluate-symlin-in-adolescent-subjects-with-type-1-diabetes-mellitus-6845https://curecurrent.com/trials/evaluation-of-a-nutritional-product-for-people-with-type-2-diabetes-6846https://curecurrent.com/trials/mechanistic-study-of-the-systolic-blood-pressure-lowering-effect-of-dapagliflozin-in-type-2-diabetes-6847https://curecurrent.com/trials/skin-blood-flow-in-patients-with-type-1-diabetes-mellitus-compared-to-normal-controls-6848https://curecurrent.com/trials/an-open-label-study-examining-the-long-term-safety-of-exenatide-given-twice-daily-to-patients-with-type-2-diabetes-melli-6849https://curecurrent.com/trials/evaluation-of-the-effect-on-glucose-control-of-ac2993-in-patients-with-type-2-diabetes-mellitus-treated-with-a-sulfonylu-6850https://curecurrent.com/trials/extension-study-for-2993-112-6851https://curecurrent.com/trials/evaluation-of-the-effect-on-glucose-control-of-ac2993-in-patients-with-type-2-diabetes-mellitus-treated-with-metformin-6852https://curecurrent.com/trials/study-examining-exenatide-long-acting-release-in-subjects-with-type-2-diabetes-6853https://curecurrent.com/trials/evaluation-of-the-effect-on-glucose-control-of-ac2993-in-patients-with-type-2-diabetes-mellitus-6854https://curecurrent.com/trials/pf-04523655-dose-escalation-study-and-evaluation-of-pf-04523655-with-without-ranibizumab-in-diabetic-macular-edema-dme-6855https://curecurrent.com/trials/study-of-the-safety-of-substituting-exenatide-for-insulin-in-patients-using-insulin-and-oral-antidiabetic-agents-6856https://curecurrent.com/trials/effect-of-exenatide-on-24-hour-blood-glucose-profile-compared-with-placebo-in-patients-with-type-2-diabetes-6857https://curecurrent.com/trials/effect-of-exenatide-monotherapy-on-glucose-control-in-subjects-with-type-2-diabetes-mellitus-6858https://curecurrent.com/trials/a-study-to-evaluate-the-pharmacokinetics-pharmacodynamics-and-tolerability-of-exenatide-in-adolescent-subjects-with-type-6859https://curecurrent.com/trials/safety-and-efficacy-of-exenatide-as-monotherapy-6860https://curecurrent.com/trials/study-to-examine-the-effect-on-glucose-control-and-safety-tolerability-of-exenatide-given-two-times-a-day-to-subjects-wi-6861https://curecurrent.com/trials/safety-and-efficacy-of-exenatide-in-patients-with-type-2-diabetes-using-thiazolidinediones-or-thiazolidinediones-and-met-6862https://curecurrent.com/trials/sugar-text-a-randomized-controlled-trial-of-a-text-message-intervention-for-women-with-diabetes-in-pregnancy-6863https://curecurrent.com/trials/evaluation-of-the-effect-on-glucose-control-and-the-safety-and-tolerability-of-ac2993-in-patients-with-type-2-diabetes-m-6864https://curecurrent.com/trials/multiple-dose-study-of-pf-05231023-in-adult-subjects-who-have-poor-lipid-control-with-and-without-type-2-diabetes-mellit-6865https://curecurrent.com/trials/mechanisms-by-which-strength-training-ameliorates-the-metabolic-syndrome-6866https://curecurrent.com/trials/fasting-predictors-of-ogtt-and-mmtt-response-6867https://curecurrent.com/trials/long-term-use-cgm-system-assessment-in-adult-athletes-with-diabetes-mellitus-6868https://curecurrent.com/trials/clinical-study-to-compare-various-dosing-and-titration-guidelines-of-insulin-delivered-via-v-go-in-patients-with-type-2-6869https://curecurrent.com/trials/effect-of-lik066-on-glucose-absorption-in-patients-with-type-2-diabetes-mellitus-6870https://curecurrent.com/trials/northern-manhattan-diabetes-community-outreach-project-6871https://curecurrent.com/trials/effects-of-vitamin-c-and-e-on-endothelial-function-in-adolescent-diabetes-6872https://curecurrent.com/trials/financial-incentives-for-medication-adherence-6873https://curecurrent.com/trials/study-of-an-intervention-to-improve-problem-list-accuracy-and-use-6874https://curecurrent.com/trials/a-study-of-the-effect-of-ly2189265-on-blood-pressure-and-heart-rate-in-type-2-diabetes-6875https://curecurrent.com/trials/novel-type-2-diabetes-mellitus-preventive-therapies-6876https://curecurrent.com/trials/safety-and-efficacy-of-cbx129801-in-patients-with-type-1-diabetes-6877https://curecurrent.com/trials/metformin-and-transient-hyperglycemia-6878https://curecurrent.com/trials/pharmacokinetics-pharmacodynamics-and-safety-of-alogliptin-in-children-adolescents-and-adults-with-type-2-diabetes-melli-6879https://curecurrent.com/trials/outpatient-characterization-of-the-variability-of-insulin-secretory-parameters-in-the-meal-tolerance-and-the-maximal-sti-6880https://curecurrent.com/trials/a-study-in-participants-with-type-2-diabetes-mellitus-6881https://curecurrent.com/trials/study-of-oasis-ultra-in-diabetic-foot-ulcers-6882https://curecurrent.com/trials/effect-of-medium-chain-fatty-acids-on-cognitive-function-during-acute-hypoglycemia-in-patients-with-type-1-diabetes-6883https://curecurrent.com/trials/diabetes-visual-function-supplement-study-6884https://curecurrent.com/trials/efficacy-and-safety-of-androgel-in-the-treatment-of-hypogonadal-and-low-testosterone-men-with-type-2-diabetes-6885https://curecurrent.com/trials/a-study-in-participants-with-type-2-diabetes-mellitus-award-3-6886https://curecurrent.com/trials/the-cantata-d2-trial-canagliflozin-treatment-and-trial-analysis-dpp-4-inhibitor-second-comparator-trial-6887https://curecurrent.com/trials/insulin-secretion-in-diabetes-before-and-after-glycemic-control-6888https://curecurrent.com/trials/safety-and-tolerability-of-ascending-intravenous-doses-of-pf-05231023-in-adult-subjects-with-type-2-diabetes-6889https://curecurrent.com/trials/telerehabilitation-intervention-to-promote-exercise-for-diabetes-6890https://curecurrent.com/trials/diabetes-in-the-elderly-prospective-study-6891https://curecurrent.com/trials/a-research-trial-of-aralast-np-in-new-onset-diabetes-retain-part-ii-6892https://curecurrent.com/trials/online-wound-electronic-medical-record-owemr-to-decrease-amputations-in-diabetics-6893https://curecurrent.com/trials/intensive-insulin-therapy-in-patients-undergoing-coronary-artery-bypass-surgery-6894https://curecurrent.com/trials/free-fatty-acid-induced-hypertension-in-obese-subjects-with-type-2-diabetes-6895https://curecurrent.com/trials/the-medical-college-of-georgia-play-project-exercise-dose-and-insulin-sensitivity-in-obese-children-6896https://curecurrent.com/trials/antioxidant-treatment-of-type-2-diabetes-6897https://curecurrent.com/trials/sugar-replacement-sweeteners-and-blood-sugar-control-6898https://curecurrent.com/trials/evaluation-of-the-yofimeter-glucometer-6899https://curecurrent.com/trials/arthritis-foundation-exercise-program-10-keys-to-healthy-aging-prevention-research-center-6900https://curecurrent.com/trials/a-study-in-adults-with-type-2-diabetes-6901https://curecurrent.com/trials/comprehensive-postpartum-screening-strategies-for-women-with-gestational-diabetes-mellitus-gdm-6902https://curecurrent.com/trials/insulin-action-during-pregnancy-in-woman-at-high-risk-for-gestational-diabetes-6903https://curecurrent.com/trials/lobag30-diet-in-patients-on-metformin-6904https://curecurrent.com/trials/hypoglycemia-associated-autonomic-failure-in-type-1-dm-q2-6905https://curecurrent.com/trials/a-phase-1-open-label-safety-study-of-nka-in-patients-with-type-2-diabetes-6906https://curecurrent.com/trials/metabolic-causes-of-thrombosis-in-type-2-diabetes-question-1-6907https://curecurrent.com/trials/hypoglycemia-associated-autonomic-failure-in-type-1-dm-6908https://curecurrent.com/trials/studies-of-organ-transplantation-in-animals-and-man-6909https://curecurrent.com/trials/effects-of-ly2189265-on-glycemic-control-in-participants-with-type-2-diabetes-6910https://curecurrent.com/trials/a-study-of-dose-titration-of-ly2189265-in-overweight-participants-with-type-2-diabetes-mellitus-6911https://curecurrent.com/trials/individual-differences-in-diabetes-risk-role-of-sleep-disturbances-6912https://curecurrent.com/trials/diabetes-depression-care-management-adoption-trial-6913https://curecurrent.com/trials/effects-of-uri-on-diabetic-subjects-utilizing-technosphere-insulin-after-a-meal-challenge-6914https://curecurrent.com/trials/a-2-month-safety-follow-up-trial-6915https://curecurrent.com/trials/simulated-diabetes-training-for-resident-physicians-6916https://curecurrent.com/trials/sitagliptin-in-combination-with-metformin-and-sulfonylurea-6917https://curecurrent.com/trials/a-study-to-compare-analytes-in-blood-collected-using-an-investigational-collection-device-with-a-commercial-predicate-6918https://curecurrent.com/trials/a-study-to-compare-analyte-levels-in-blood-collected-using-an-investigational-collection-device-with-a-commercial-predic-6919https://curecurrent.com/trials/randomized-placebo-controlled-2-period-single-blind-sequential-multiple-ascending-dose-study-6920https://curecurrent.com/trials/effects-of-pioglitazone-on-high-density-lipoprotein-hdl-function-in-persons-with-diabetes-6921https://curecurrent.com/trials/a-safety-and-efficacy-study-comparing-naltrexone-sr-bupropion-sr-and-placebo-in-obese-subjects-with-type-2-diabetes-6922https://curecurrent.com/trials/a-pilot-intervention-study-of-health-coaching-to-promote-diabetes-self-care-in-the-community-6923https://curecurrent.com/trials/postpartum-glucose-tolerance-with-levonorgesterel-iud-use-in-women-with-recent-gestational-diabetes-6924https://curecurrent.com/trials/dulce-digital-project-dulce-2-0-texting-study-6925https://curecurrent.com/trials/naturlose-d-tagatose-efficacy-evaluation-trial-6926https://curecurrent.com/trials/microbes-and-bariatric-surgery-6927https://curecurrent.com/trials/vascular-effects-of-carvedilol-versus-metoprolol-in-hypertensive-patients-with-type-2-diabetes-6928https://curecurrent.com/trials/telehealth-remote-patient-monitoring-study-in-people-with-type-2-diabetes-6929https://curecurrent.com/trials/enhanced-spanish-drug-label-study-to-promote-patient-understanding-and-use-6930https://curecurrent.com/trials/performance-evaluation-of-a-non-invasive-glucose-monitor-as-compared-to-cgm-data-acquired-by-the-ipro2-6931https://curecurrent.com/trials/ranolazine-when-added-to-glimepiride-in-subjects-with-type-2-diabetes-mellitus-6932https://curecurrent.com/trials/molecular-and-clinical-effects-of-green-tea-and-fermented-papaya-preparation-on-diabetes-and-cardiovascular-diseases-6933https://curecurrent.com/trials/surgical-treatment-of-type-2-diabetes-in-non-morbidly-obese-patients-6934https://curecurrent.com/trials/vitamin-d-glucose-control-and-insulin-sensitivity-in-african-americans-6935https://curecurrent.com/trials/feasibility-study-of-a-modular-control-to-range-system-in-type-1-diabetes-mellitus-6936https://curecurrent.com/trials/exercise-and-diabetes-an-observational-study-of-exercise-and-blood-glucose-control-6937https://curecurrent.com/trials/clinical-utility-of-sudoscan-in-the-pediatric-population-6938https://curecurrent.com/trials/a-pilot-study-examining-a-reinforcement-approach-to-improve-diabetes-management-6939https://curecurrent.com/trials/diabetes-virtual-trek-obesity-and-diabetes-prevention-through-science-enrichment-6940https://curecurrent.com/trials/obesity-and-diabetes-prevention-through-science-enrichment-6941https://curecurrent.com/trials/a-clinical-study-to-evaluate-the-effect-of-naturlose-tagatose-6942https://curecurrent.com/trials/chronic-care-management-patient-relationship-management-proof-of-concept-6943https://curecurrent.com/trials/effect-of-inpatient-diabetes-management-on-outpatient-glycemic-control-6944https://curecurrent.com/trials/type-2-diabetes-evaluation-of-ranolazine-in-subjects-with-chronic-stable-angina-6945https://curecurrent.com/trials/a-safety-and-efficacy-study-of-canagliflozin-in-older-patients-55-to-80-years-of-age-with-type-2-diabetes-mellitus-6946https://curecurrent.com/trials/safety-and-efficacy-of-lx4211-with-metformin-in-type-2-diabetes-patients-with-inadequate-glycemic-control-on-metformin-6947https://curecurrent.com/trials/study-of-a-cell-phone-system-to-improve-health-of-youth-with-diabetes-6948https://curecurrent.com/trials/type-1-diabetes-mellitus-effect-on-bone-mineral-density-6949https://curecurrent.com/trials/clinical-trial-evaluating-the-efficacy-and-safety-of-technosphere-inhalation-insulin-ti-inhalation-powder-using-the-gen2-6950https://curecurrent.com/trials/evaluation-of-a-lifestyle-intervention-for-employees-with-prediabetes-6951https://curecurrent.com/trials/safety-and-efficacy-of-technosphere-insulin-inhalation-powder-ti-inhalation-powder-when-an-optimal-dose-is-taken-with-va-6952https://curecurrent.com/trials/education-counseling-and-drug-therapy-to-reduce-symptoms-of-metabolic-syndrome-6953https://curecurrent.com/trials/comparison-of-psyllium-and-microcrystalline-cellulose-on-glycemic-measures-in-subjects-with-impaired-fasting-glucose-6954https://curecurrent.com/trials/ranolazine-monotherapy-in-subjects-with-type-2-diabetes-mellitus-6955https://curecurrent.com/trials/effectiveness-study-of-community-based-peer-led-education-on-weight-loss-and-diabetes-6956https://curecurrent.com/trials/effect-of-genetic-variants-in-mate1-and-oct3-on-the-pharmacodynamics-of-metformin-in-african-americans-6957https://curecurrent.com/trials/clinical-trial-evaluating-technosphere-insulin-versus-insulin-aspart-in-subjects-with-type-1-diabetes-mellitus-over-a-24-6958https://curecurrent.com/trials/a-study-to-compare-the-effect-of-giving-dulaglutide-using-an-auto-injector-versus-a-manual-syringe-6959https://curecurrent.com/trials/study-of-medical-assistant-health-coaching-in-primary-care-for-patients-with-chronic-conditions-6960https://curecurrent.com/trials/comparison-of-lantus-and-neutral-protamine-hagedorn-nph-insulin-in-the-dawn-phenomenon-6961https://curecurrent.com/trials/30-week-parallel-group-comparison-study-of-linagliptin-pioglitazone-5-15-5-30-and-5-45-mg-qd-versus-respective-monothera-6962https://curecurrent.com/trials/effect-of-different-fixed-pramlintide-insulin-dose-ratios-on-postprandial-glucose-in-t1dm-6963https://curecurrent.com/trials/efficacy-of-lubiprostone-in-combination-with-standard-peg-preparation-6964https://curecurrent.com/trials/comparison-of-technosphere-insulin-versus-technosphere-powder-placebo-in-insulin-naive-subjects-with-type-2-diabetes-mel-6965https://curecurrent.com/trials/renal-effects-of-two-iodinated-contrast-media-in-patients-at-risk-undergoing-computed-tomography-6966https://curecurrent.com/trials/a-pilot-study-for-the-evaluation-of-minocycline-as-a-microglia-inhibitor-in-the-treatment-of-diabetic-macular-edema-6967https://curecurrent.com/trials/safety-of-inhaled-insulin-with-type-1-and-type-2-diabetes-6968https://curecurrent.com/trials/efficacy-and-safety-in-subjects-with-type-2-diabetes-receiving-subcutaneous-basal-insulin-and-prandial-inhalation-of-tec-6969https://curecurrent.com/trials/safety-and-efficacy-of-technosphere-insulin-inhalation-powder-and-lantus-compared-to-humalog-and-lantus-over-16-weeks-6970https://curecurrent.com/trials/efficacy-and-safety-of-prandial-inhalation-of-technosphere-insulin-in-combination-with-metformin-or-technosphere-insulin-6971https://curecurrent.com/trials/efficacy-safety-of-inhaled-insulin-in-type-1-diabetes-6972https://curecurrent.com/trials/an-open-label-multi-center-international-three-year-safety-and-tolerability-follow-on-trial-6973https://curecurrent.com/trials/a-study-designed-to-compare-2-dose-strengths-of-ti-inhalation-powder-in-adults-with-type-1-diabetes-mellitus-and-to-comp-6974https://curecurrent.com/trials/assess-measurements-of-wireless-cardiac-output-device-6975https://curecurrent.com/trials/weight-loss-study-for-people-with-type-2-diabetes-6976https://curecurrent.com/trials/the-ohsu-pregnancy-exercise-nutrition-pen-program-6977https://curecurrent.com/trials/phase-1-multicenter-single-ascending-dose-study-to-assess-the-safety-tolerability-pharmacokinetic-and-pharmacodynamic-re-6978https://curecurrent.com/trials/assessing-the-risk-of-developing-type-ii-diabetes-using-serum-biomarkers-in-patients-diagnosed-with-obstructive-sleep-ap-6979https://curecurrent.com/trials/a-study-in-adults-with-type-1-diabetes-6980https://curecurrent.com/trials/a-study-comparing-the-effect-of-dulaglutide-with-liraglutide-in-type-2-diabetes-6981https://curecurrent.com/trials/a-study-in-participants-with-type-2-diabetes-mellitus-award-4-6982https://curecurrent.com/trials/a-study-of-the-effect-of-ly2189265-on-two-blood-pressure-drugs-6983https://curecurrent.com/trials/respond-restoring-equilibrium-and-wound-stimulation-to-promote-healing-of-non-healing-dfus-6984https://curecurrent.com/trials/a-study-of-the-effect-of-dulaglutide-on-how-the-body-handles-oral-contraceptive-in-healthy-female-participants-6985https://curecurrent.com/trials/a-study-to-compare-the-concentrations-of-ly2189265-after-different-methods-of-administration-to-healthy-volunteers-6986https://curecurrent.com/trials/a-study-of-ly2189265-and-sitagliptin-in-participants-with-type-2-diabetes-6987https://curecurrent.com/trials/a-study-of-the-effect-of-dulaglutide-on-the-action-of-warfarin-in-healthy-participants-6988https://curecurrent.com/trials/study-of-safety-tolerability-and-pharmacokinetics-of-single-oral-jtt-251-doses-in-healthy-and-type-2-diabetic-subjects-6989https://curecurrent.com/trials/a-study-of-the-effect-of-dulaglutide-on-how-body-handles-digoxin-in-healthy-participants-6990https://curecurrent.com/trials/efficacy-and-safety-of-bi-10773-in-combination-with-insulin-in-patients-with-type-2-diabetes-6991https://curecurrent.com/trials/effect-of-fish-oil-omega-3-fatty-acids-on-arteries-6992https://curecurrent.com/trials/the-impact-of-fitness-on-vascular-dysfunction-in-adolescents-with-type-1-diabetes-6993https://curecurrent.com/trials/safety-and-efficacy-of-bgp-15-in-patients-with-type-2-diabetes-mellitus-6994https://curecurrent.com/trials/topical-plurogel-pn-for-the-treatment-of-mildly-infected-diabetic-foot-ulcers-6995https://curecurrent.com/trials/the-effect-of-ethanol-on-overnight-glucose-regulation-in-type-2-6996https://curecurrent.com/trials/study-to-evaluate-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-lgd-6972-in-healthy-subjects-and-subjects-6997https://curecurrent.com/trials/topical-plurogel-n-for-the-treatment-of-mildly-infected-diabetic-foot-ulcers-6998https://curecurrent.com/trials/a-phase-3-study-of-ranolazine-in-subjects-with-type-2-diabetes-who-are-inadequately-controlled-on-metformin-alone-6999https://curecurrent.com/trials/a-trial-to-assess-the-efficacy-and-safety-of-spm-927-in-subjects-with-painful-distal-diabetic-neuropathy-7000